PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 1  
  
 
 
 
A PHASE 1, OPEN -LABEL, FIXED -SEQUENCE STUDY TO EVALUATE THE 
EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE -DOSE 
PHARMACOKINETICS  OF PF-07081532  IN OVERWEIGHT  OR OBESE  ADULT 
PARTICIPANTS  
 
 
 
 
 
Study  Intervention  Number:  PF-07081532  
Study  Intervention  Name:  NA 
US IND Number:  CCI  
EudraCT/EU  CT Number:  NA 
ClinicalTrials.gov ID: NA 
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C3991041  
Phase:  1 
Brief  Title:  A Drug -Drug  Interaction  Study  to Examine  the Impact  of Itraconazole  and 
Cyclosporine on PF -07081532 Pharmacokinetics in Overweight or Obese Adult 
Participants.  
 
 
This document  and accompanying  materials  contain  confidential  information  belonging  to Pfizer.  Except  as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this 
information  in confidence  and not copy  or disclose  it to others  (except  where  required  by applicable  law) or 
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer 
must be promptly notified.  

PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 2  
 Document  History  
 
Document  Version  Date  
Original  protocol  31 January  2023  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 3  
 TABLE  OF CONTENTS  
LIST  OF TABLES  ................................ ................................ ................................ .....................  8 
1. PROTOCOL  SUMMARY  ................................ ................................ ................................ ..... 9 
1.1. Synopsis  ................................ ................................ ................................ .....................  9 
1.2. Schema ................................ ................................ ................................ .....................  15 
1.3. Schedule  of Activities  ................................ ................................ ..............................  16 
2. INTRODUCTION  ................................ ................................ ................................ ................  21 
2.1. Study  Rationale  ................................ ................................ ................................ ........  21 
2.2. Background  ................................ ................................ ................................ ..............  21 
2.2.1.  Nonclinical Pharmacology  ................................ ................................ ..........  22 
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  ................................ ..........  22 
2.2.3.  Nonclinical  Safety  ................................ ................................ .......................  22 
2.2.4.  Clinical  Overview  ................................ ................................ .......................  23 
2.2.4.1.  Clinical Pharmacokinetics  ................................ .........................  23 
2.3. Benefit/Risk Assessment  ................................ ................................ .........................  24 
2.3.1.  Risk Assessment  ................................ ................................ .........................  25 
2.3.2.  Benefit Assessment  ................................ ................................ .....................  28 
2.3.3.  Overall Benefit/Risk Conclusion  ................................ ................................  28 
3. OBJECTIVES  AND  ENDPOINTS  ................................ ................................ .....................  28 
4. STUDY  DESIGN  ................................ ................................ ................................ .................  29 
4.1. Overall  Design  ................................ ................................ ................................ .........  29 
4.2. Scientific  Rationale  for Study  Design  ................................ ................................ ...... 29 
4.2.1.  Choice  of Contraception/Barrier  Requirements  ................................ ..........  30 
4.2.2.  Collection  of Retained  Research  Samples  ................................ ...................  30 
4.3. Justification for Dose  ................................ ................................ ...............................  30 
4.4. End of Study  Definition  ................................ ................................ ...........................  31 
5. STUDY POPULATION  ................................ ................................ ................................ ...... 31 
5.1. Inclusion  Criteria  ................................ ................................ ................................ ..... 31 
5.2. Exclusion Criteria  ................................ ................................ ................................ .... 32 
5.3. Lifestyle  Considerations  ................................ ................................ ..........................  35 
5.3.1.  Contraception  ................................ ................................ ..............................  36 
5.3.2.  Meals and Dietary  Restrictions  ................................ ................................ ... 36 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 4  
 5.3.3.  Caffeine,  Alcohol,  and Tobacco  ................................ ................................ . 37 
5.3.4.  Activity  ................................ ................................ ................................ ...... 37 
5.4. Screen  Failures  ................................ ................................ ................................ ........  37 
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  ................................ . 37 
6.1. Study  Intervention(s)  Administered  ................................ ................................ ........  38 
6.1.1.  Administration  ................................ ................................ ............................  39 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ..............  39 
6.2.1.  Preparation  and Dispensing  ................................ ................................ ........  40 
6.3. Assignment to Study Intervention  ................................ ................................ ..........  41 
6.4. Blinding  ................................ ................................ ................................ ..................  41 
6.5. Study  Intervention  Compliance  ................................ ................................ ..............  41 
6.6. Dose  Modification  ................................ ................................ ................................ .. 41 
6.7. Continued  Access to  Study  Intervention After  the End  of the Study  .....................  41 
6.8. Treatment of Overdose  ................................ ................................ ...........................  41 
6.9. Prior  and Concomitant  Therapy  ................................ ................................ ..............  42 
6.9.1.  Rescue  Medicine  ................................ ................................ ........................  43 
6.9.1.1.  Management  of Nausea  and Vomiting  ................................ ..... 43 
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  ................................ ................................ ...........  43 
7.1. Discontinuation of Study  Intervention  ................................ ................................ .... 43 
7.1.1.  Potential Cases of Acute Kidney  Injury  ................................ .....................  44 
7.2. Participant Discontinuation/Withdrawal From the Study  ................................ ...... 45 
7.2.1.  Withdrawal  of Consent  ................................ ................................ ..............  45 
7.3. Lost to Follow -up ................................ ................................ ................................ ... 45 
8. STUDY  ASSESSMENTS  AND  PROCEDURES  ................................ ..............................  46 
8.1. Administrative  Procedures  ................................ ................................ ......................  46 
8.2. Efficacy  Assessments  ................................ ................................ .............................  47 
8.3. Safety Assessments  ................................ ................................ ................................ . 47 
8.3.1.  Physical  Examinations  ................................ ................................ ...............  47 
8.3.2.  Vital  Signs  ................................ ................................ ................................ .. 48 
8.3.2.1.  Blood Pressure and Pulse Rate ................................ .................  48 
8.3.2.2.  Temperature  ................................ ................................ ..............  48 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 5  
 8.3.3.  Electrocardiograms  ................................ ................................ ......................  48 
8.3.4.  Clinical  Safety  Laboratory  Assessments  ................................ .....................  49 
8.3.5.  COVID -19 Specific  Assessments  ................................ ...............................  50 
8.3.6.  Management of Hypoglycemia  ................................ ................................ ... 50 
8.3.6.1.  Definition  and Severity  of Categorization  of 
Hypoglycemic  Adverse  Event  ................................ ...........................  50 
8.3.6.2.  Glucometer Monitoring of Glucose  ................................ ...........  51 
8.3.7.  Pregnancy  Testing  ................................ ................................ .......................  52 
8.3.8.  Suicidal  Ideation  and Behavior  Risk Monitoring  ................................ ........  52 
8.3.8.1.  Columbia  Suicide  Severity  Rating  Scale  ................................ ... 52 
8.3.8.2.  Patient  Health  Questionnaire -9 (PHQ -9) ................................ ... 52 
8.3.8.3.  Referral  to a Mental  Health  Professional  ................................ ... 52 
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  ..................  53 
8.4.1.  Time Period and Frequency  for Collecting AE and SAE Information  ....... 53 
8.4.1.1.  Reporting SAEs to Pfizer Safety  ................................ ...............  54 
8.4.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF ...................  54 
8.4.2.  Method  of Detecting  AEs and SAEs  ................................ ...........................  55 
8.4.3.  Follow -Up of AEs and SAEs  ................................ ................................ ...... 55 
8.4.4.  Regulatory  Reporting Requirements for SAEs  ................................ ...........  55 
8.4.5.  Environmental Exposure, Exposure During Pregnancy  or 
Breastfeeding, and Occupational Exposure  ................................ .....................  55 
8.4.5.1.  Exposure During Pregnancy  ................................ ......................  56 
8.4.5.2.  Exposure  During  Breastfeeding  ................................ .................  57 
8.4.5.3.  Occupational Exposure  ................................ ..............................  58 
8.4.6.  Cardiovascular  and Death  Events  ................................ ................................  58 
8.4.7.  Disease  -Related  Events  and/or  Disease  -Related  Outcomes  Not 
Qualifying  as AEs or SAEs  ................................ ................................ ..............  58 
8.4.8.  Adverse  Events  of Special  Interest  ................................ .............................  58 
8.4.8.1.  Lack of Efficacy  ................................ ................................ ........  58 
8.4.9.  Medical  Device  Deficiencies  ................................ ................................ ...... 58 
8.4.10.  Medication  Errors  ................................ ................................ ......................  58 
8.5. Pharmacokinetics  ................................ ................................ ................................ ..... 59 
8.6. Genetics  ................................ ................................ ................................ ...................  60 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 6  
 8.7. Biomarkers  ................................ ................................ ................................ ..............  60 
8.8. Immunogenicity  Assessments  ................................ ................................ ................  61 
8.9. Health  Economics  ................................ ................................ ................................ ... 61 
9. STATISTICAL  CONSIDERATIONS  ................................ ................................ ................  61 
9.1. Statistical Hypothesis  ................................ ................................ .............................  61 
9.2. Analysis  Sets ................................ ................................ ................................ ...........  61 
9.3. Statistical Analyses  ................................ ................................ ................................ . 62 
9.3.1.  Pharmacokinetic Analyses  ................................ ................................ .........  62 
9.3.1.1.  Derivation of Pharmacokinetic Parameters  ..............................  62 
9.3.1.2.  Statistical  Methods  for PK Data ................................ ...............  63 
9.3.2.  Safety  Analyses  ................................ ................................ ..........................  64 
9.3.2.1.  Electrocardiogram Analyses  ................................ .....................  64 
9.3.2.2.  Mental  Health  ................................ ................................ ...........  64 
9.4. Interim  Analyses  ................................ ................................ ................................ ..... 65 
9.5. Sample Size Determination  ................................ ................................ ....................  65 
10. SUPPORTING   DOCUMENTATION   AND   OPERATIONAL  
CONSIDERATIONS ................................ ................................ ................................ ..........  66 
10.1. Appendix  1: Regulatory,  Ethical, and  Study  Oversight Considerations  ...............  66 
10.1.1.  Regulatory  and Ethical Considerations  ................................ ....................  66 
10.1.1.1.  Reporting of Safety Issues and Serious Breaches of the 
Protocol  or ICH GCP  ................................ ................................ ........  66 
10.1.2.  Informed  Consent  Process  ................................ ................................ ....... 67 
10.1.3.  Data  Protection  ................................ ................................ .........................  68 
10.1.4.  Committees  Structure  ................................ ................................ ...............  68 
10.1.4.1.  Data  Monitoring  Committee  ................................ ...................  68 
10.1.5.  Dissemination  of Clinical Study  Data ................................ ......................  68 
10.1.6.  Data  Quality  Assurance  ................................ ................................ ............  69 
10.1.7.  Source  Documents  ................................ ................................ ...................  71 
10.1.8.  Study  and Site Start and Closure  ................................ ..............................  71 CCI CCI CCI 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 7  
 10.1.9.  Publication Policy  ................................ ................................ ....................  72 
10.1.10.  Sponsor’s Medically  Qualified Individual  ................................ .............  73 
10.2. Appendix 2: Clinical Laboratory  Tests  ................................ ................................  74 
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating,  Follow -Up, and Reporting  ................................ ................................ ..... 75 
10.3.1.  Definition  of AE ................................ ................................ .......................  75 
10.3.2.  Definition  of an SAE ................................ ................................ ................  76 
10.3.3.  Recording/Reporting  and Follow -Up of AEs and/or  SAEs During  
the Active Collection Period  ................................ ................................ ...........  77 
10.3.4.  Reporting  of SAEs  ................................ ................................ ...................  81 
10.4. Appendix  4: Contraceptive  and Barrier  Guidance  ................................ ................  82 
10.4.1.  Male Participant Reproductive Inclusion Criteria  ................................ ... 82 
10.4.2.  Female  Participant  Reproductive  Inclusion  Criteria  ................................  82 
10.4.3.  Woman  of Childbearing  Potential  ................................ ............................  82 
10.4.4.  Contraception  Methods  ................................ ................................ ............  83 
CCI  
10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments  ....... 86 
10.7. Appendix 7: Kidney  Safety: Monitoring Guidelines  ................................ ............  88 
10.7.1.  Laboratory  Assessment of Change in Kidney  Function and 
Detection of Kidney Injury  ................................ ................................ .............  88 
10.7.2.  Age-Specific  Kidney  Function  Calculation Recommendations  ...............  88 
10.7.2.1.  Adults  (18 Years  and Above) —2021 CKD -EPI 
Equations  ................................ ................................ ..........................  88 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  
Abnormalities  ................................ ................................ ................................ .. 88 
10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  ................................ ... 89 
10.9. Appendix 9: Abbreviations  ................................ ................................ ...................  91 
11. REFERENCES  ................................ ................................ ................................ ..................  95 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 8  
 LIST OF TABLES  
Table  1. Study  Schedule of Assessment  ................................ ................................ . 16 
Table  2. PK Blood  Sampling  - Periods  1 and 2 ................................ .....................  20 
Table  3. PK Blood  Sampling  – Period  3 ................................ ................................  20 
Table  4. Plasma  PK Parameters  for PF-07081532  ................................ .................  62 
Table  5. Protocol -Required  Safety  Laboratory  Assessments  ................................ . 74 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 9  
 1. PROTOCOL  SUMMARY  
1.1. Synopsis  
Protocol  Title:  A Phase  1, Open -Label,  Fixed -Sequence  Study  to Evaluate  the Effect  of 
Itraconazole  and Cyclosporine  on the Single -Dose  Pharmacokinetics  of PF-07081532  in 
Overweight or Obese Adult Participants.  
Brief Title: A Drug -Drug Interaction Study to Examine the Impact of Itraconazole and 
Cyclosporine  on PF-07081532  Pharmacokinetics  in Overweight  or Obese  Adult  Participants.  
Regulatory  Agency  Identification  Number(s):  
 
US IND Number:  CCI  
EudraCT  Number:  NA 
ClinicalTrials.gov  ID: NA 
Pediatric  Investigational  Plan  Number:  NA 
Protocol  Number:  C3991041  
Phase:  1 
 
Rationale: This is a Phase 1, open -label, fixed -sequence study to evaluate the effect of 
multiple doses of itraconazole and a single dose of cyclosporine on the single -dose PK of 
PF-07081532  in otherwise  healthy,  overweight  or obese  adult  participants  and to generate 
safety, tolerability, and PK data for further clinical development.  
Objectives  and Endpoints:  
 
Objectives  Endpoints  
Primary:  Primary:  
• To estimate  the effect  of MD itraconazole  on the 
SD PK of PF -07081532 in otherwise healthy, 
overweight or obese participants.  • PF-07081532  PK parameter:  AUC inf (if data 
permita otherwise AUC last) 
• To estimate  the effect  of SD cyclosporine  on the 
SD PK of PF -07081532 in otherwise healthy, 
overweight or obese participants.  • PF-07081532  PK parameter:  AUC inf (if data 
permita otherwise AUC last) 
Secondary:  Secondary:  
• To evaluate  the safety  and tolerability  of 
PF-07081532 administered separately and in 
combination  with itraconazole  or cyclosporine 
in otherwise healthy, overweight or obese 
participants.  • Assessment of TEAEs, clinical laboratory 
abnormalities,  vital signs,  body  weight,  and ECG 
parameters.  
• Assessment  of mental  health  as determined  by 
C-SSRS and PHQ -9. 
• To evaluate the effects of itraconazole or 
cyclosporine  on additional  PK parameters  for 
PF-07081532.  • Additional  plasma  PK parameters  for 
PF-07081532:  Cmax and Tmax; and CL/F,  Vz/F, t½, 
as data permit.  
a. Should  it be deemed  that too few AUC inf estimates  (eg, less than 12 for a single  treatment)  are obtained 
from the evaluable participants, AUC last may be selected as the primary endpoint for CSR reporting.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 10  
 Overall  Design:  
This is a Phase  1, open -label,  fixed -sequence,  3-period  study  to evaluate  the effect  of 
multiple doses of itraconazole and a SD of cyclosporine on the single -dose PK of  
PF-07081532  in otherwise  healthy,  overweight  or obese,  adult  female  and male  participants. 
The 3 study periods will be conducted consecutively without a break.  
Number of Participants:  
Approximately  16 participants  will be enrolled  in the study  such that approximately 
12 evaluable participants complete the study.  
Note:  “Enrolled”  means  a participant’s  or their legally  authorized  representative’s  agreement 
to participate in a clinical study following completion of the informed consent process and 
assignment to study intervention. A participant will be considered enrolled if the informed 
consent is not withdrawn prior to participating in any study activity. Potential participants 
who are screened for the purpose of determining eligibility for the study, but do not 
participate in the study, are not considered enrolled, unless otherwise specified by the 
protocol.  
Study Population:  
Key inclusion and exclusion  criteria are listed  below:  
Inclusion  Criteria  
Participants  must  meet  the following  key inclusion  criteria  to be eligible  for enrollment  into 
the study:  
1. Otherwise  healthy  female  and male  participants  must  be at least 18 years  of age at the 
time of signing the ICD (healthy is defined as no clinically relevant abnormalities 
identified by a detailed medical history, physical examination, including blood 
pressure and pulse rate measurement, standard 12 -lead ECG and clinical laboratory 
tests).  
• Women  can be of child -bearing  potential,  but cannot  be pregnant,  breastfeeding, 
or planning to become pregnant while participating in the study, may not be 
taking either oral contraceptives or non -oral hormonal contraceptives (with the 
exception of implantable progestogen only or intrauterine hormone releasing 
system), and must avoid vaccination with live attenuated vaccines.  
2. BMI:  ≥25.0  kg/m2 at Screening.  
3. Stable  body  weight,  defined  as <5 kg change  (per participant  report)  for 90 days 
before Screening.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 11  
 Exclusion  Criteria  
Participants  with any of the following  characteristics/conditions  will be excluded:  
Medical Conditions  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary,  gastrointestinal,  cardiovascular,  hepatic,  psychiatric,  neurological,  or 
allergic  disease  (including  drug allergies,  but excluding  untreated,  asymptomatic, 
seasonal allergies at the time of dosing).  
• Any condition  possibly  affecting  drug absorption  (eg, prior  bariatric  surgery, 
gastrectomy, cholecystectomy or any area of intestinal resection, active 
inflammatory bowel disease or pancreatic insufficiency).  
• Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the 
risk of study  participation  or, in the investigator’s  judgment,  make  the participant 
inappropriate for the study.  
• Known  intolerance  or hypersensitivity  to GLP -1R agonists.  
• Known  hypersensitivity  to itraconazole  or cyclosporine.  
2. Diagnosis  of type 1 or type 2 diabetes  mellitus  or secondary  forms  of diabetes  at 
Screening. Note : women with prior diagnoses of gestational diabetes during 
pregnancy only are eligible if they meet the other eligibility criteria.  
3. Any malignancy  not considered  cured  (except  basal  cell carcinoma  and squamous  cell 
carcinoma of the skin); a study participant is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years (from Screening). Anyone with 
any history of pancreatic CA will be excluded, even if it was resected and they were 
considered ‘cured’.  
4. Personal  or family  history  of MTC  or MEN2,  or study  participants  with suspected 
MTC per the investigator’s judgment.  
5. Acute  pancreatitis,  a history  of repeated  episodes  of acute  pancreatitis,  or history  of 
chronic pancreatitis.  
6. Symptomatic  gallbladder  disease.  
7. Medical  history  or characteristics  suggestive  of genetic  or syndromic  obesity  or 
obesity induced by other endocrinological disorders (eg, Cushing Syndrome).  
8. History  of depressive  disorder  or history  of other  severe  psychiatric  disorders  (eg, 
schizophrenia or bipolar disorder) within the last 2 years from screening.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 12  
 9. Known medical history of active liver disease, including chronic hepatitis B or C, 
primary biliary cirrhosis, alcoholic liver disease, primary sclerosing cholangitis, 
autoimmune  hepatitis,  overlap  syndrome,  or prior  known  drug-induced  liver injury.  
10. History  of HIV infection.  
11. Any lifetime history  of a suicide attempt.  
12. Use of any medications  that are: 
• Moderate  or strong  CYP3A4/5  and/or  CYP2C19  inhibitors  within  14 days or 
5 half -lives (whichever is longer),  
• Moderate  or strong  CYP3A  and/or  CYP2C19  inducers  within  14 days or 5 
half-lives (whichever is longer), or  
• Systemic  therapy  with inhibitors  of OATP  transporters  within 14  days or 
5 half-lives (whichever  is longer)  prior to the  first dose  of study  intervention.  
13. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at 
least 5 minutes  of supine  rest. BP should  be measured  in triplicate  and the average  of 
the 3 BP values should be used to determine the participant’s eligibility. Note : At 
Screening, the participant’s arm circumference should be measured (eg, using a 
flexible anthropometric tape) at the midpoint of the length of the upper arm, and the 
appropriate cuff selected and used throughout the study.  
14. Standard  12-lead ECG  that demonstrates  clinically  relevant  abnormalities  that may 
affect participant safety or interpretation of study results (eg, QTcF interval  
>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial 
infarction  (documented  assessment),  ST-T interval  changes  suggestive  of myocardial 
ischemia, second - or third -degree AV block, or serious bradyarrhythmias or 
tachyarrhythmias).  
• If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be 
repeated 2 more times and the average of the 3 QTcF or QRS values should be 
used to determine  the participant’s  eligibility.  Computer  interpreted  ECGs  should 
be overread by a physician experienced in reading ECGs before excluding 
participants.  
15. Participants  with ANY  of the following  abnormalities  in clinical  laboratory  tests at 
Screening, as assessed by the study specific laboratory and confirmed by a single 
repeat test, if deemed necessary:  
• HbA1c  ≥6.5%.  
• AST  or ALT  level  ≥1.25 ×  ULN.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 13  
 • Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert’s 
syndrome  may have  direct  bilirubin  measured  and would  be eligible  for this study 
provided the direct bilirubin level is ≤ ULN.  
• TSH  >1.5 × ULN  or <LLN.  
• Serum  calcitonin  > ULN.  
• Amylase  or lipase  > ULN.  
• Fasting  blood  glucose  ≥126  mg/dL.  
• Fasting  C-peptide  not within  normal  limit.  
• eGFR  <75 mL/min/1.73  m2 as calculated  by the CKD -EPI equation.  
Study Arms and Duration:  
The total duration  of participation  from  the Screening  Visit  to the F/U telephone  contact  will 
be approximately 82 days or 12 weeks, approximately 3 weeks of which will be conducted 
on an inpatient  basis.  The 21-day inpatient  portion  of the study  will be conducted  as follows:  
Period  1: Days  -1 to 5 (Study  Days -1 to 5; participants  are admitted  to the CRU  on Day -1), 
40 mg SD PF -07081532 on Day 1;  
Period  2: Days  1 to 5 (Study  Days  6 to 10), 40 mg SD PF-07081532  plus 600 mg SD 
cyclosporine on Day 1;  
Period  3: Days  1 to 10 (Study  Days  11 to 20; participants  are discharged  from  the CRU  on 
Study Day 20), 200 mg itraconazole QD ×9 days plus 40 mg SD PF -07081532 on Day 4.  
A telephone  F/U contact  will occur  28-35 days from  the last dose of study  intervention 
(Period 3, Day 9).  
 
Study  Intervention(s)  
Intervention  Name  PF-07081532  Itraconazole  Cyclosporine  
Arm  Name  
(group  of participants 
receiving a specific 
treatment or no 
treatment)  All participants  All participants  All participants  
Unit  Dose  Strength  20 mg 10 mg/mL  100 mg 
Route of 
Administration  Oral Oral Oral 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 14  
  
Study  Intervention(s)  
Use Substrate  Perpetrator  Perpetrator  
IMP  or AxMP  IMP AxMP  AxMP  
 
 
Study  Arm(s)  
Arm  Title  Period  1: PF-07081532  
single  dose Period  2: Cyclosporine  + 
PF-07081532  Period  3: Itraconazole  + 
PF-07081532  
Arm  Type  No intervention  Experimental  (DDI)  Experimental  (DDI)  
Arm 
Description  Participants will 
receive PF -07081532 
as a single  40 mg dose 
on Day 1.  Participants will receive a single  
40 mg dose of PF -07081532 and a 
single  600 mg dose of cyclosporine 
on Day 1.  Participants  will receive 
itraconazole 200 mg  
QD × 9 days plus a single  
40 mg dose of PF-07081532 
on Day 4.  
 
No dose adjustments  or reductions  will be permitted  in this study.  
Statistical  Methods:  
Approximately  12 evaluable  participants  will complete  the study.  
Natural log e transformed AUC inf of PF -07081532 administered without cyclosporine or 
coadministered  with cyclosporine  will be analyzed  using  a mixed  effect  model  with treatment 
as a fixed effect and participant as a random effect. Estimates of the adjusted mean 
differences (Test/Reference) and corresponding 90% CIs will be obtained from the models.  
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference)  and 90% CIs for 
the ratios. The test treatment will be ‘PF -07081532 40 mg SD and cyclosporine’ (Period 2), 
which will be reported separately in comparison to the reference treatment of ‘PF -07081532 
40 mg SD without cyclosporine’ (Period 1).  
Natural log e transformed AUC inf of PF -07081532 administered without itraconazole or 
coadministered  with itraconazole  will be analyzed  using  a mixed  effect  model  with treatment 
as a fixed effect and participant as a random effect. Estimates of the adjusted mean 
differences (Test/Reference) and corresponding 90% CIs will be obtained from the models. 
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference)  and 90% CIs for 
the ratios. The test treatment will be ‘PF -07081532 40 mg SD and itraconazole’ (Period 3), 
which will be reported separately in comparison to the reference treatment of ‘PF -07081532 
40 mg SD without itraconazole’ (Period 1).  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 15  
 Ethical Considerations:  
PF-07081532  is not expected  to provide  any long-term clinical  benefit  to the healthy  adult 
female and male participants in this study. This study is designed primarily to generate 
safety, tolerability, and PK data for further clinical development.  
Based  on experience  with PF-07081532  and other  marketed  GLP -1R agonists,  the potential 
risks for PF -07081532 include thyroid C -cell tumors, pancreatitis, hypoglycemia, renal 
function impairment, gastrointestinal adverse reactions, suicidal ideation and behavior, 
changes in heart rate and blood pressure, weight loss, and/or acute gallbladder disease.  
Participants will be expected to commit time and may experience some discomfort while 
undergoing  study  assessments.  In addition,  participants  of childbearing  potential  must  agree 
to use appropriate contraception methods and avoid vaccination with live attenuated 
vaccines . 
1.2. Schema  
Not applicable.  
PF-0708 1532 
Protocol C3991041 
 Final  Protocol 31 January 2023   
PFIZER  CONFIDENTIAL  
CT02-GSOP Clinical Phanna cology Pro tocol Templ ate (01 April  2022 ) 
Page  16  
  
1.3. Schedule of Activities 
The SoA  table provides an overview of the  protocol visit s and procedure s. Refer to the STUDY ASSESSMENTS AND 
PROCEDURES  section  of the protocol  for detailed infonnatio n on each procedure and  assessment  required  for comp liance  with the 
protocol.  
The investigator may schedule  visits (unplanned  visits) in addit ion to those  listed in the SoA table, in order to conduct evaluatio ns or 
assessment s requi red to protect the well-being of the paiiic ipant. 
 
Table 1. Study Schedule  of Assess ment  
 
Visit Identifiel' 
Abbrevia tions used in this 
table  may be fonnd in 
Annendix 9 . Scr·een Period 1 Period 2 Period 3 F/U (Phone 
Call) ET Notes 
Study Day  -1 lto5 6to 10 11 to 20 47 to 54   
Days Relative to Day 1 D-28 to D-2 D-1 Dl toD5 Dl to D5 Dl to DlO 28-35 Days  1. All screening  should  be done  '.S28  days  before 
the firs t dose.  
2.  Day relati ve to start of study inter vention 
(Day 1). 
3.  In thi s study , follow -up is to be conducted via 
phone  contact  28 to 35 days  after  admini stration 
of the final  dose of study  intervention (Period 3  
Dav 9, Studv  Dav 19). 
Info,med  consent X       • Info,med  consent should be obtained prior  to nndergoing  
any study-specific procedm·e s. 
CRU  confinement   X ➔ ➔ X    
Inclu sion/exclu sion criteria X X       
Medic al/medic ation histo,y X X    X  • Including  histo,y collection of alcohol and tobacco use. 
Physical exam  X X      • Comple te PE conducted  at Screening  or admission, and as 
required  at PI' s discretion. 
Bodyweight  X X X(D5) X(D5 ) X (DlO)  X  
PF-0708 1532 
Protocol C3991041  
Final Protocol 31 January  2023  
PFIZER  CONFIDENTIAL  
CT02-GSOP Clinical Phannacology Pro tocol Templ ate (01 April  2022 ) 
Page  17  
  
 
Table  1. Study Schedule  of Assessment  
 
Visit Identifiel' 
Abbreviations  used in this 
table may be fonnd in 
Annendix 9 . Scr·een Period 1 Period 2 Period 3 F/U (Phone 
Call) ET Notes 
Study Day  -1 lto5 6to 10 11 to 20 47 to 54   
Days Relative to Day 1 D-28 to D-2 D-1 Dl toD5 Dl to D5 Dl to DlO 28-35 Days  1. All screening  shou ld be done '.S28  days  before 
the first dose. 
2.  Day relati ve to start of study inter vention 
(Day 1). 
3. In this study , follow -up is to be conducte d via 
phone  contact  28 to 35 days  after admini stration  
of the final  dose of study intervention (Period  3 
Dav 9. Studv Dav 19). 
Safety laborato,y  (hema tology , 
chemistiy, and UA) X X  X(D5  
chemi stiy 
only) X  X • See Table  5 for a comple te list of clinic al lab tests. 
• Period 3 collecti on prior  to discharge  on Day 10. 
Calcitonin, amylase, lipase, 
HbAlC , TSH, C-Peptide  X       •  An ovemigh t fast is required  prior  to calcitonin sample 
collecti on. 
Dem ograph y X       • Including  height and weight. 
Serum  and urine  pregnanc y 
test (WOCBP onl y) X X   X (DlO )  X •  Pregnanc y tests will also be done  whene ver 1 men stmal 
cycle is missed during the active treatment period (or 
when po tential pregnanc y is otherwise suspected) and at 
the end of the studv nrior  to discharoe on Period  3 Dav 10. 
Contracep tion check  X X    X X  
FSH X       • For any female who has been ameno1Theic  for at least 
12 consecuti ve months. 
Urine  dmg testing X X      • Participan ts may underg o random  mine  dmg testing at the 
discretion of the investigator. 
Single  12-Lead ECG  X  X X X  X • Pre-dose Day 1 in each period , and prior  to discharge on 
Period 3 Day 10. 
Blood pressure, pulse rate, and 
body temperature  X  X X X  X • Pre-dose Day 1 in each period , and prior  to discharge on 
Period 3 Day 10. 
• Bodv temoerattu ·e will be taken  at Sreenin   onlv. 
PF-07081532  
Protocol  C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02-GSOP C linical Phannacology Pro tocol Templa te (01 April  2022) 
Page  18  
  
Table  1. Study Schedule  of Assessment  
 
Visit Identifiel' 
Abbreviations used  in this 
table may be fonnd in  
A  endix  9. Scr·een Period 1 
 
 
 
-1 lto5 
D-1 Dl toD5 Period 2 Period 3 F/U (Phone 
Call) ET Notes 
 Study Day  
D-28 to D-2 6to 10 
Dl to D5 11 to 20 
Dl to DlO 47 to 54 
28-35 Days   
1. All screening  shou ld be done '.S28  days before 
the first dose. 
2.  Day relative  to start of study  intervention 
(Day 1).  
3. In this study , follow -up is to be conducte d via 
phone contact  28 to 35 days after administration 
of the final  dose of  study intervention  (Period 3 
Da 9. Stud  Da 19 . Days Relative to Day 1 
  
HIV , HBsAg, HBcAb , HCV 
RNA ,HCVAb  X       
 
 
X  
 
C-SSRS  and PHQ -9  
X  
X    
X (Dl0) 
COVID -19 assessments  X      • See Section  8.3.5. 
• See Table  2 and Table  3 for specifics. 
• See Table  3. 
• See Table  2. 
• See blood  sampling  timepoin ts in Table  2 for Period s 1 
and 2 and Table  3 for Period  3. Study  interven tion 
admini stration PF-07081532   X(D1) X(D l) X(D4)  
Study  interven tion 
admini stration itra.conazo le    X (Dl-9)  
Study  interven tion 
admini stration cyclo sporine    X(D l)   
Pha1macokinetic  blood 
sampling : PF-0708 1532  D1-5 D1-5 D4-10 X 

PF-07081532  
Protocol  C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02-GSOP C linical Phannacology Pro tocol Templa te (01 April  2022) 
Page  19  
  
Table  1. Study Schedule  of Assess ment  
 
Visit Identifiel' 
Abbreviations used  in this 
table may be fonnd in 
Aooendix 9 . Scr·een Period 1 Period 2 Period 3 F/U (Phone 
Call) ET Notes 
Study Day  -1 lto5 6to 10 11 to 20 47 to 54   
Days Relative to Day 1 D-28 to D-2 D-1 Dl toD5 Dl to D5 Dl to DlO 28-35 Days  1. All screening  shou ld be done  '.S28  days  before 
the first dose. 
2.  Day relative  to start of study  intervention 
(Day 1). 
3.  In this study , follow -up is to be conducte d via 
phone contact  28 to  35 days  after administration 
of the final  dose of  study intervention (Period 3 
Dav 9. Studv  Dav 19). 
CRU  discharge      X (DlO)    
Serious  and nonserious AE 
monitoring  X ➔ ➔ ➔ ➔ ➔ ➔ • See Section  8.4.3  for follow -up AE and SAE  assessments . 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 20   
  
 
Table 2. PK Blood Sampling - Periods 1 and 2 
 
Visit  Identifier  Periods  1 and 2 Notes  
Period  Day 1 2 3 4 5   
Hours  After  Dose  0 0.5 1 2 4 6 8 10 12 14 24 36 48 72 96 120 • Hour  0 = predose  sample 
collection.  
• The 120 -hour PK samples 
in Periods 1 and 2 are the 
same as the 0 -hour PK 
samples  in Periods  2 and 3, 
respectively.  
Study  intervention  administration  PF-07081532  X                 
Study intervention administration cyclosporine  
(Period 2 only)  X                 
PK blood sampling PF -07081532  X X X X X X X X X X X X X X X X  
 
Table 3. PK Blood  Sampling  – Period  3 
 
Visit  Identifier  Period  3 Notes  
Period  Day 1 2 3 4 5 6 7 8 9 10  
Hours  After  Dose     0 0.5 1 2 4 6 8 10 12 14 24 36 48 72 96 120 144 Hour  0 = predose  sample 
collection  
Study  intervention  administration 
PF-07081532     X                  
Study  intervention  administration 
itraconazole  X X X X          X  X X X X   
PK blood  sampling     X X X X X X X X X X X X X X X X X  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 21  
 2. INTRODUCTION  
GLP -1 is a neuroendocrine hormone that is predominantly released from the small intestine 
in response to food intake.1 GLP -1 activation of the GLP -1R stimulates insulin release, 
inhibits  glucagon  secretion  in a glucose -dependent  manner,  and delays  gastric  emptying.2,3 In 
addition, GLP -1 has been shown to increase satiety and suppress food intake.4 
PF-07081532 is an orally administered, potent and selective GLP -1R agonist in development 
as adjunct  to diet and exercise,  to improve  glycemic  control  in T2DM,  and for chronic  weight 
management in a population that is overweight with co -morbidities or who have obesity.  
2.1. Study Rationale  
In vitro  data indicate  that PF-07081532  is a substrate  for both CYP3A  and OATP;  therefore, 
an assessment of the impact of inhibition of these pathways is needed. This study will 
evaluate the impact of the strong CYP3A inhibitor, itraconazole, and the OATP inhibitor, 
cyclosporine, on the single -dose PK of PF -07081532.  
The purpose  of this Phase  1, open -label,  fixed -sequence  study  is to evaluate  the effect  of 
multiple doses of itraconazole and a single dose of cyclosporine on the SD PK of  
PF-07081532  in otherwise  healthy,  overweight  or obese  adult  participants,  and to generate 
safety, tolerability, and PK data for further clinical development.  
2.2. Background  
T2DM is estimated to affect more than 424 million people worldwide,5 and the prevalence of 
T2DM within the US is estimated to range from 12 to 14%.6 Patients with poorly controlled 
T2DM have an increased risk of developing complications associated with both 
microvascular and macrovascular disease, including nephropathy, neuropathy, retinopathy, 
cardiovascular disease and stroke; and are at 2 to 4 times increased risk of mortality than 
adults who do not have diabetes.7 While existing pharmacological options for the treatment  
of diabetes  may provide  satisfactory  glycemic  control  for some  patients,  there  remains  a large 
number of patients who do not achieve target glycated HbA1c levels, suggesting a need for 
additional therapeutic options.  
Obesity is a chronic disease that is associated with serious co -morbidities, including T2DM, 
dyslipidemia,  hypertension,  atherosclerosis,  obstructive  sleep  apnea  and certain  cancers,8 and 
is also associated with increased all -cause mortality.9 The global burden of obesity is high 
with more than 600 million adults estimated to have obesity worldwide. In addition, the 
prevalence of obesity has doubled in more than 70 countries since 1980 and poses a major 
public health challenge.10 First line treatment for obesity is lifestyle intervention including 
diet, exercise and behavioral therapy. While effective in many  patients, lifestyle intervention 
is often not sustainable, and many patients regain weight after initial weight loss.11 
Pharmacotherapy has been approved for the long -term treatment of obesity and can be a 
useful adjunct to lifestyle intervention to augment and maintain weight loss.  
Marketed  injectable  GLP -1R agonists  have  demonstrated  robust  glycemic  efficacy,  weight 
loss, and cardiovascular safety, with more than one marketed agent demonstrating  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 22  
 cardiovascular benefit.12 Based on the clinical experience with injectable GLP -1R agonists, 
an oral, small molecule GLP -1R agonist is expected to improve glucose control and reduce 
HbA1c  levels  in patients  with T2DM,  and to decrease  appetite  and body  weight,  resulting  in 
weight loss in patients with T2DM and obesity, while avoiding the subcutaneous injection 
required by currently available peptidic GLP -1R agonists.  
2.2.1.  Nonclinical Pharmacology  
Refer  to the IB for details on  the nonclinical  pharmacology  of PF-07081532.  
2.2.2.  Nonclinical  Pharmacokinetics  and Metabolism  
In rats and monkeys  following  single  IV and oral dosing,  PF-07081532  exhibited  low CL p 
(13 and 0.6 mL/min/kg, respectively), with low to moderate steady -state V ss (0.76 and  
0.21 L/kg,  respectively),  leading  to a t½ of 1.6 hours  in rats and 8.8 hours  in monkeys.  Renal 
excretion was negligible in both species, and biliary excretion was minimal in rats. The 
systemic  exposure  (assessed  by AUC  and Cmax) of PF-07081532  following  oral repeat  doses 
generally increased in a dose -proportional manner.  
In vitro,  PF-07081532  was a substrate  for the hepatic  uptake  transporter,  OATP1B3,  but not 
for OATP1B1. Coadministration of an OATP inhibitor with PF -07081532 in monkeys 
resulted in a notable increase in the plasma AUC exposure of PF -07081532 and 
corresponding decrease in CL, suggesting a potential role for OATP transport in the uptake 
limited CL in monkeys.  
PF-07081532 was extensively metabolized via oxidative CYP and conjugation UGT 
pathways. CYP -mediated metabolism accounted for 67% of the hepatic metabolism, with 
CYP3A (31%) being the predominant CYP isoform. The contribution of non -CYP 
metabolism was estimated to be 33% of the hepatic metabolism, which was due to 
glucuronidation  (24%)  and chemical  hydrolysis  (9%).  UGT1A1  and UGT1A3  were  primarily 
responsible  for the glucuronidation  of PF-07081532,  with possible  minor  contributions  by the 
non-hepatic UGT isoforms, UGT1A7 and UGT1A8.  
Refer  to the IB for more  details on  the nonclinical  PK and metabolism  of PF -07081532.  
2.2.3.  Nonclinical Safety  
PF-07081532  has been  evaluated  in a comprehensive  nonclinical  safety  package  that includes 
toxicity studies up to 6 months (in rats) and 9 months (in monkeys), as well as reproductive 
and developmental toxicology studies in rats and rabbits. Based on the nonclinical studies 
conducted,  the target  organs  and systems  identified  with PF-07081532  administration  include 
the heart, stomach and liver.  
In the 6-month  pivotal  study  with 1-month  recovery  phase  in rats, oral gavage  administration 
of PF -07081532 for 6 months did not result in any mortality or adverse effects in any of the 
study parameters or endpoints evaluated resulting in the high dose being the NOAEL. The 
exposure at this dose provided exposure margins of 40× and 29× (C max and AUC 24, 
respectively) over the highest clinical dose planned (260 mg QD).  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 23  
 In the 9 -month pivotal study in cynomolgus monkeys, PF -07081532 was administered by 
oral gavage with doses titrating up. There were no adverse findings in the endpoints 
evaluated  in this study.  The primary  effects  were  consistent  with the expected  pharmacology 
of the test article which included decreased body weight associated with decreased food 
consumption, and secondary changes in clinical chemistry and hematology parameters. At 
the NOAEL dose, the exposure margins were 5.2× and 4.6× (C max and AUC 24, respectively) 
over the highest clinical dose (260 mg QD) planned.  
The NOAELs  in the 6-month  rat or 9-month  monkey  pivotal  toxicity  studies  were 
100 mg/kg/day  in both species,  with associated  unbound  Cmax of 768 ng/mL  and unbound 
AUC 24 of 8270 ng•h/mL  in rats and unbound C max of 98.5 ng/mL and unbound AUC 24 of 
1300 ng•h/mL in monkeys.  
PF-07081532  was not genotoxic  in either  in vitro  or in vivo assays.  In addition,  PF-07081532 
was negative in the 3T3 Neutral Red uptake Phototoxicity  Test, indicating that PF -07081532 
is not phototoxic.  
Refer  to the IB for more  details  on the nonclinical  safety  of PF-07081532.  
2.2.4.  Clinical Overview  
As of issuance of this protocol, 2 Phase 1 studies evaluating PF -07081532 (C3991001 and 
C3991002) have been completed. In total, 88 participants have been randomized, including 
22 healthy  adult  participants,  51 adult  participants  with T2DM,  and 15 adult  participants  with 
obesity. A total of 74 unique participants have been exposed to at least 1 dose of  
PF-07081532.  The safety  profile  of PF-07081532  was assessed  in these  2 completed  clinical 
studies and, to date, administration of PF -07081532 at single doses up to 200 mg and 
multiple doses up to 180 mg QD has been considered safe, with the majority of the TEAEs 
being mild in intensity.  
One Phase  1 study,  C3991003,  recently  concluded.  This inpatient  study  enrolled  participants 
with T2DM inadequately controlled on metformin, and participants with obesity, to receive 
PF-07081532 or placebo QD for 42 days. The starting dose for the first cohort of this study 
was 20 mg QD of PF-07081532,  with subsequent  dose levels  determined  based  on emerging 
data; the maximum dose administered was 80 mg QD. While final clinical data from this 
study are not yet available, as of issuance of this protocol, there have been no deaths, SAEs 
or AEs of severe intensity reported.  
Refer  to the IB for more  details  on the clinical  safety  of PF-07081532.  
2.2.4.1.  Clinical Pharmacokinetics  
The clinical  PK of PF-07081532  in adult  participants  have  been  evaluated  to date in 
2 completed  studies  (C3991001  and C3991002).  The results  of these  completed  studies  are 
summarized in the PF -07081532 IB.  
In Study C3991001 following administration of single oral doses of PF -07081532 under 
fasted  conditions  to healthy  participants,  PF-07081532  was absorbed  relatively  rapidly  with a 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 24  
 median  Tmax of 1.00 to 4.02 hours  (individual  Tmax values  ranged  between  0.5 and 6 hours). 
Based  on the individual plasma concentration -time profiles, the absorption phase exhibited 
multiple peaks, especially at the higher dose levels. Mean t ½ ranged from 18.03 to  
20.90  hours  across  all doses.  Plasma  Cmax increased  less than proportionally  across  the entire 
investigated dose range (from 10 mg to 200 mg), while plasma AUC inf increased less than 
proportionally from 10 mg to 30 mg and approximately proportionally from 30 mg to  
200 mg. Inter -participant  variability  for PF-07081532  exposure  was low to moderate  and 
ranged from 9% to 36% CV for C max and 15% to 44% CV for AUC inf across all doses.  
Overall,  the results  indicate  that PF-07081532  may be administered  without  regard  to food.  
In Study  C3991002  following  administration  of PF-07081532,  Cmax was observed  at 
1 to 2 hours on Day 1, and 2 to 8 hours following the last dose on Day 28 or 42. Across all 
dose groups,  the mean  t½ ranged  from  20.70  to 26.50  hours.  PF-07081532  exposure  generally 
increased in an approximately dose -proportional manner across the dose range studied, and 
accumulation of less than 2.1 -fold was observed. Urinary recovery of unchanged  
PF-07081532 was low, with less than 0.2% of the dose recovered in the 24 -hour dosing 
interval following last dose administration. Interparticipant variability for PF -07081532 
exposure ranged from 17% to 51% CV for C max and 15% to 62% CV for AUC tau across all 
doses.  No substantial  differences  in PF-07081532  exposure  (Cmax and AUC tau) were  observed 
between participants with T2DM and obesity either after single dose (Day 1, 10 mg) or 
multiple dose (Day 28, 120 mg and Day 42, 180 mg) administration.  
In Study  C3991003  following  single -dose (Day  1) and multiple -dose (Day  42) administration 
of PF -07081532, peak plasma PF -07081532 concentrations (C max) were observed at  
1 to 2 hours and 2 to 5 hours, respectively. Terminal t ½ averaged 24.37 to 26.04 hours 
following  multiple -dose administration  (Day  42). PF-07081532  exposure  (Cmax and AUC tau) 
increased in an approximately dose -proportional manner across the dose range studied.  
Accumulation with QD dosing was less than 2 -fold. No substantial differences were 
observed  in the achieved  exposures  (both  Cmax and AUC tau) between  participants  with T2DM 
and obesity either after single -dose (Day 1, 20 mg) or multiple -dose (Day 42, 60 mg) 
administration.  
Refer  to the IB for more  details  on the clinical  PK of PF-07081532.  
2.3. Benefit/Risk  Assessment  
PF-07081532  is not expected  to provide  any clinical  benefit  to healthy  participants.  This 
study  is designed primarily  to generate  safety, tolerability, and pharmacokinetic data for 
further clinical development.  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of PF-07081532  may be found  in the IB, which  is the SRSD  for this study.  The 
SRSD for the site sourced itraconazole and cyclosporine capsule products are the 
corresponding USPIs.13,14 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 25  
 2.3.1.  Risk  Assessment  
 
Potential Risk of 
Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Study  Intervention:  PF-07081532  
Thyroid  C-cell tumors  The potential risks are based on product 
labeling for injectable GLP -1R agonists 
(ie, liraglutide,  dulaglutide,  semaglutide, 
and exenatide) due to dose -dependent 
and treatment duration -dependent 
thyroid C -cell tumors in nonclinical 
studies in rats and mice at clinically 
relevant exposures.  
Of note,  similar  tumors  were  not seen in 
rodent  studies  with PF-07081532,  likely 
as PF -07081532 does not stimulate 
rodent GLP -1 receptors.  Potential participants with a 
personal or family history of 
medullary thyroid carcinoma or 
Multiple Endocrine Neoplasia 
syndrome  type 2 are excluded  from 
the clinical development program.  
Thyroid  function  tests are included 
in the clinical trial protocols to 
monitor participants’ thyroid 
function.  
Pancreatitis  The potential  risks  are based  on product 
labeling  for injectable  GLP -1R agonists 
(ie, liraglutide, exenatide, semaglutide 
and dulaglutide).  
One SAE of obstructive pancreatitis has 
been observed in the PF -07081532 
clinical trial program, which was 
considered  to be treatment -related  by the 
investigator, but unrelated by the 
sponsor.  Per exclusion criteria, potential 
participants  with acute  pancreatitis 
or a history  of chronic  pancreatitis 
are not eligible for study entry.  
Serum amylase and lipase are 
monitored  during  clinical  studies.  
Hypoglycemia  Clinical trials with injectable GLP -1R 
agonists have not demonstrated an 
increased risk for hypoglycemia. But 
when  administered  in combination  with 
anti-diabetic agents that are known to 
have  an increased  risk of hypoglycemia 
(such as insulin or sulfonylureas), an 
increased risk for hypoglycemia was 
observed.  
Participants with obesity who do not 
have co -existing T2DM would not be 
taking  anti-diabetic  agents  and therefore 
would not be expected to have an 
increased risk for hypoglycemia.  
A low overall frequency of generally 
mild hypoglycemia  has been  reported  in 
the PF -07081532 clinical development 
program to date.  Anti-diabetic medications are 
prohibited in this study, and blood 
glucose  is monitored  as a part of the 
lab assessments during the study.  
Participants  are informed  about  the 
signs and symptoms of 
hypoglycemia and are monitored 
for these symptoms during the 
study.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 26  
  
Potential Risk of 
Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Impairment  in renal 
function  Potential risks are based on product 
labeling for injectable GLP -1R agonists, 
and predominantly  occur  in patients  with 
significant nausea, vomiting, and 
dehydration.  
In the clinical  trial program  only one 
mild adverse event (Preferred Term 
Blood  creatinine  increased)  has been 
observed.  Per exclusion criteria, potential 
participants  with significant  renal 
impairment are not eligible for 
study entry.  
Renal  function  is monitored  by lab 
assessments of serum urea, 
creatinine and eGFR.  
Hydration  will be encouraged,  and 
reduced fluid intake and evidence 
of dehydration,  if detected,  will be 
treated  by close  clinical  follow -up. 
Gastrointestinal  adverse 
reactions  The potential  risks  are based  on product 
labeling  for injectable  GLP -1R agonists 
(ie, liraglutide, exenatide, semaglutide 
and dulaglutide).  
Gastrointestinal AEs, the majority of 
which  were  mild in severity,  have  been 
observed in the clinical program with  
PF-07081532.  In nonclinical  studies  with 
PF-07081532, gastrointestinal adverse 
effects were observed in rats and 
monkeys.  Participants  are monitored  during 
the clinical studies to prevent 
potential sequelae of any severe 
gastrointestinal reactions,  
eg, dehydration.  
Hydration will be encouraged and 
concomitant  medication  for nausea 
is permitted in the study.  
Diabetic  retinopathy 
complications  The potential  risk is based  on the product 
labeling for the injectable GLP -1R 
agonist semaglutide and dulaglutide in 
patients with T2DM.  
There  are no nonclinical  or clinical  data 
involving PF -07081532 to suggest an 
increased risk of diabetic retinopathy 
complications.  Potential  participants  with diabetes 
mellitus are excluded from this 
clinical study.  
Suicidal  ideation  and 
behavior  The potential  risk is based  on the product 
labeling for the injectable GLP -1R 
agonists liraglutide and semaglutide for 
obesity based on long -term studies.  
Suicidal  ideation  has not been  observed 
in the PF -07081532 clinical studies to 
date. Suicidal ideation and behavior, 
along  with symptoms  of depression, 
will be monitored at specified 
intervals during the study using the 
C-SSRS  and PHQ -9 questionnaires, 
with referral to a MHP for further 
evaluation if needed.  
Changes  in heart  rate Potential risk is based on the product 
labeling for the injectable GLP -1R 
agonists,  liraglutide  and semaglutide,  for 
T2DM and obesity.  
Modest  increases  in HR have  been  noted 
in the early clinical studies with  
PF-07081532, with most values 
remaining  within  the normal  range.  HR is monitored  during  the clinical 
study.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 27  
  
Potential Risk of 
Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Declines  in body  weight  Decreased  appetite  and body  weight  loss 
have been reported for marketed  
GLP -1R agonists and declines in body 
weight  have  been  noted  at higher  doses 
of PF -07081532.  Weight is collected at multiple 
timepoints  and will be monitored 
throughout the trial.  
Acute  gallbladder  disease  Potential risk is based on the product 
labeling for the injectable GLP -1R 
agonists,  semaglutide  and liraglutide,  for 
T2DM and obesity.  
Acute  gallbladder  disease  has not been 
observed in the PF -07081532 clinical 
trial program to date.  Participants with symptomatic 
gallbladder  disease  are excluded 
from this clinical study.  
Participants  are monitored  for AEs 
and laboratory tests that may 
suggest development of acute 
gallbladder disease.  
Study  Intervention:  Itraconazole  
Rare cases of serious 
hepatotoxicity, including 
liver failure and death. 
There have been reports  
of congestive heart  
failure. In post -marketing 
experience, heart failure 
was more frequently 
reported in patients 
receiving a total daily 
dose of 400 mg although 
there were also cases 
reported among those 
receiving  lower  total daily 
doses. Transient or 
permanent hearing loss 
has been reported in 
patients receiving 
treatment with 
itraconazole.  Risk based  on product  labeling.  Multiple  oral doses  of 200 mg QD 
for 9 days  are administered  in this 
study and pose minimal risk.  
Participants  will be monitored  in an 
inpatient clinical research unit.  
Study  Intervention:  Cyclosporine  
Systemic hypertension, 
hepatotoxicity and 
nephrotoxicity; the risk 
increases  with increasing 
dose and duration of 
cyclosporine therapy.  
Renal dysfunction, 
including structural 
kidney damage, is a 
potential consequence of 
cyclosporine, and 
therefore, renal function 
must  be monitored  during 
therapy.  Risk based  on product  labeling.  A single oral dose of 600 mg is 
administered  in the study  and poses 
minimal risk. Participants will be 
monitored in an inpatient clinical 
research unit.  
Hydration will be encouraged and 
concomitant  medication  for nausea 
is permitted in the study.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 28  
  
Potential Risk of 
Clinical  Significance  Summary  of Data/Rationale  for Risk Mitigation  Strategy  
Other  
Risk of COVID -19 
exposure  during  study  Study  participants  could  be infected  with 
the SARS -CoV -2 virus during study 
participation. This could lead to 
increased health risk for this participant 
and others in the study.  Participants undergo COVID -19 
specific  assessments  at admission  to 
study site and when symptoms  
arise.  
2.3.2.  Benefit  Assessment  
While PF -07081532 is not expected to provide any significant long -term clinical benefit to 
the healthy, overweight or obese participants in this relatively short -term study, potential 
benefits  may include  weight  loss, receiving  medical  evaluations/assessments  associated  with 
clinical study  visits (eg, physical examinations, ECGs, labs), and contributing to the process 
of developing a potential new therapy for T2DM and obesity.  
More  detailed  information  about  the known  and expected  benefits  and risks  and reasonably 
expected AEs of PF -07081532 may be found in the IB, which is SRSD, for this study.  
2.3.3.  Overall  Benefit/Risk Conclusion  
Taking into account the measures to minimize risk to study participants, the potential risks 
identified  in association  with PF-07081532  are justified  by the anticipated  benefits  that may 
be afforded to participants who are overweight or obese.  
3. OBJECTIVES  AND  ENDPOINTS  
 
Objectives  Endpoints  
Primary:  Primary:  
• To estimate  the effect  of MD itraconazole  on the 
single -dose PK of PF -07081532 in otherwise 
healthy, overweight or obese participants.  • PF-07081532  PK parameter:  AUC inf (if data 
permita otherwise AUC last) 
• To estimate  the effect  of SD cyclosporine  on the 
single -dose PK of PF -07081532 in otherwise 
healthy, overweight or obese participants.  • PF-07081532  PK parameter:  AUC inf (if data 
permita otherwise AUC last) 
Secondary:  Secondary:  
• To evaluate  the safety  and tolerability  of 
PF-07081532 administered separately and in 
combination  with itraconazole  or cyclosporine 
in otherwise healthy, overweight or obese 
participants.  • Assessment of TEAEs, clinical laboratory 
abnormalities,  vital signs,  body  weight,  and ECG 
parameters.  
• Assessment  of mental  health  as determined  by 
C-SSRS and PHQ -9. 
• To evaluate the effects of itraconazole or 
cyclosporine  on additional  PK parameters  for 
PF-07081532.  • Additional  plasma  PK parameters  for 
PF-07081532:  Cmax and Tmax; and CL/F,  Vz/F, t½, 
as data permit.  
a. Should  it be deemed  that too few AUC inf estimates  (eg, less than 12 for a single  treatment)  are obtained 
from the evaluable participants, AUC last may be selected as the primary endpoint for CSR reporting.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 29  
 4. STUDY  DESIGN  
4.1. Overall  Design  
This is a Phase 1, open -label, fixed -sequence, 3 -period study to evaluate the effect of 
multiple  doses  of itraconazole  and a single  dose of cyclosporine  on the single -dose PK of 
PF-07081532 in otherwise healthy, overweight or obese adult participants. The 3 study 
periods will be conducted consecutively without a break.  
All participants will provide informed consent and undergo Screening evaluations to 
determine their eligibility. Screening will occur within 28 days of the first dose of study 
intervention on Period 1 Day 1. Participants who discontinue from the study before 
completing  all assessments  may be replaced  at the discretion  of the investigator  and sponsor.  
Approximately  16 participants  will be enrolled  in the study  such that approximately 
12 evaluable participants complete the study.  
The total duration  of participation  from  the Screening  Visit  to the F/U telephone  contact  will 
be approximately 82 days or 12 weeks, approximately 3 weeks of which will be conducted 
on an inpatient  basis.  The 21-day inpatient portion  of the  study  will be conducted  as follows:  
Period  1: Days  -1 to 5 (Study  Days -1 to 5; participants  are admitted  to the CRU  on Day -1), 
40 mg SD PF -07081532 on Day 1;  
Period  2: Days  1 to 5 (Study  Days  6 to 10), 40 mg SD PF-07081532  plus 600 mg SD 
cyclosporine on Day 1;  
Period  3: Days  1 to 10 (Study  Days  11 to 20; participants  are discharged  from  the CRU  on 
Study Day 20), 200 mg itraconazole QD ×9 days plus 40 mg SD PF -07081532 on Day 4.  
A telephone  F/U contact  will occur  28-35 days from  the last dose of study  intervention 
(Period 3, Day 9).  
4.2. Scientific Rationale for  Study Design  
The purpose  of this study  is to characterize  the effect  of multiple  doses  of itraconazole  and a 
single  dose of cyclosporine  on the SD PK of PF-07081532  in otherwise  healthy,  overweight 
or obese adult participants.  
In vitro data indicate that PF -07081532 is a substrate for the hepatic uptake transporter, 
OATP1B3. Likewise, an increase in the plasma AUC exposure of PF -07081532 was 
observed  during  coadministration  of an OATP  inhibitor  in monkeys.  Therefore,  a single  dose 
of cyclosporine will be coadministered with PF -07081532 in this study to assess the impact 
of an OATP inhibitor on the single -dose PK of PF -07081532.  
In vitro  data also indicate  that CYP3A  is the predominant  CYP  isoform  contributing  to the 
metabolism of PF -07081532. Therefore, multiple doses of itraconazole will be  
co-administered  with PF-07081532  in this study  to assess  the impact  of a CYP3A  strong 
inhibitor on the single -dose PK of PF -07081532.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 30  
 PF-07081532 will be administered as a single 40 mg dose  in all 3 study  periods, and all 
dosing  will be administered  with food in order  to minimize  gastrointestinal  related  AEs.  
Participants will include overweight or obese males and females to represent the target 
population.  Additionally,  WOCBP  will be permitted  with the stipulation  that they comply 
with the contraceptive guidelines provided in Appendix 4 . 
4.2.1.  Choice of Contraception/Barrier Requirements  
Human  reproductive  safety  data are not available  for PF-07081532,  but there  is no suspicion 
of human teratogenicity based on the intended pharmacology of the compound. Therefore, 
the use of a highly effective method of contraception is required (see Appendix 4 ). 
4.2.2.  Collection  of Retained  Research  Samples  
Retained  Research  Samples  will be collected  and stored  for further  analyses  which  may,  for 
example, provide greater understanding of the study intervention.  
4.3. Justification for Dose  
The 40 mg dose of PF -07081532 has been chosen based on safety and tolerability 
considerations during co -administration of either a CYP3A or OATP inhibitor. Because PF - 
07081532 was shown to be an OATP substrate in vitro, and because co -administration of an 
OATP  inhibitor  with PF-07081532  in monkeys  resulted  in a notable  increase  in PF-07081532 
plasma AUC exposure, a conservative dose of 40 mg has been chosen in the event 
cyclosporine co -administration results in significant increases in PF -07081532 exposure 
(refer to Section 2.2.2 ). 
Itraconazole  is considered  to be a strong  inhibitor  of CYP3A.15 The 200 mg QD itraconazole 
dosing regimen (3 -day lead -in) has been chosen based on recommendations provided by  the 
Innovation  and Quality  in Pharmaceutical  Development’s  Clinical  Pharmacology  Leadership 
Group16 and is expected to provide adequate inhibition of CYP3A. Multiple DDI studies 
using 100 –200 mg/day of itraconazole with a 3 -day lead -in have demonstrated that 
adequately strong CYP3A inhibition is observed with this strategy.17,18,19 Following the  
co-administration  of itraconazole  and PF-07081532  on Day 4 of Period  3, itraconazole 
administration will continue for an additional 5 days in order to maintain inhibition of 
CYP3A throughout the PK sampling duration of PF -07081532.  
Itraconazole  is available  as either  capsules  or solution  for oral administration  and either  may 
be used when conducting DDI studies.16 The oral solution formulation will be administered 
in the current study as it provides higher systemic exposures, has less PK variability, and 
offers greater flexibility with respect to dosing (fed or fasted) compared to the capsule 
formulation.20,21 Finally, a total duration of 2 weeks of itraconazole dosing is a reasonable 
limit for minimizing  unnecessary  itraconazole  exposure and potential safety  risks associated 
with longer exposure,16 therefore, the 9 -day dosing duration planned for the current study  is 
expected to be safe and well -tolerated.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 31  
 Cyclosporine is an FDA recommended inhibitor of OATP.15 The 600 mg single dose of 
cyclosporine has been chosen based on previous experience in clinical DDI studies and is 
expected  to provide  maximal  inhibition  of OATP,  with adequate  safety  and tolerability.22,23 
4.4. End of Study Definition  
The end of the study  is defined  as the date of the last visit of the last participant  in the study.  
A participant  is considered  to have  completed  the study  if they have  completed  all periods  of 
the study, including the last visit or the last scheduled procedure shown in the SoA. 
5. STUDY POPULATION  
This study can fulfill its objectives only if appropriate participants are enrolled, including 
participants across diverse and representative racial and ethnic backgrounds. Use of a 
prescreening tool is utilized for study recruitment purposes; it will include collection of 
information that reflects the enrollment of a diverse participant population including, where 
permitted  under  local  regulations,  age, sex, and race,  and ethnicity.  The following  eligibility 
criteria are designed to select participants for whom participation in the study  is considered 
appropriate. All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular participant is suitable for this protocol.  
Prospective  approval  of protocol  deviations  to recruitment  and enrollment  criteria,  also 
known as protocol waivers or exemptions, is not permitted.  
5.1. Inclusion  Criteria  
Participants  are eligible  to be included  in the study  only if all of the following  criteria  apply:  
Age and Sex: 
1. Otherwise  healthy  female  and male  participants  must  be at least 18 years  of age at the 
time of signing the ICD (healthy is defined as no clinically relevant abnormalities 
identified by a detailed medical history, physical examination, including blood 
pressure and pulse rate measurement, standard 12 -lead ECG and clinical laboratory 
tests).  
• Women  can be of child -bearing  potential,  but cannot  be pregnant,  breastfeeding, 
or planning to become pregnant while participating in the study, may not be 
taking either oral contraceptives or non -oral hormonal contraceptives (with the 
exception of implantable progestogen only or intrauterine hormone releasing 
system), and must avoid vaccination within live attenuated vaccines. Refer to 
Appendix 4 for reproductive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2 ) participants.  
Other  Inclusion  Criteria:  
2. BMI:  ≥25.0  kg/m2 at Screening.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 32  
 3. Stable  body  weight,  defined  as <5 kg change  (per participant  report)  for 90 days 
before Screening.  
4. Participants  who are willing  and able to comply  with all scheduled  visits,  treatment 
plan, laboratory tests, lifestyle considerations, and other study procedures.  
5. Capable  of giving  signed  informed  consent  as described  in Appendix  1: Regulatory, 
Ethical, and Study Oversight Considerations , which includes compliance with the 
requirements and restrictions listed in the ICD and in this protocol.  
5.2. Exclusion  Criteria  
Participants  are excluded  from  the study  if any of the following  criteria  apply:  
Medical Conditions  
1. Evidence or history of clinically significant hematological, renal, endocrine, 
pulmonary,  gastrointestinal,  cardiovascular,  hepatic,  psychiatric,  neurological,  or 
allergic  disease  (including  drug allergies,  but excluding  untreated,  asymptomatic, 
seasonal allergies at the time of dosing).  
• Any condition  possibly  affecting  drug absorption  (eg, prior  bariatric  surgery, 
gastrectomy, cholecystectomy or any area of intestinal resection, active 
inflammatory bowel disease or pancreatic insufficiency).  
• Other medical or psychiatric condition including recent (within the past year) or 
active suicidal ideation/behavior or laboratory  abnormality  that may  increase the 
risk of study  participation  or, in the investigator’s  judgment,  make  the participant 
inappropriate for the study.  
• Known  intolerance  or hypersensitivity  to GLP -1R agonists.  
• Known  hypersensitivity  to itraconazole  or cyclosporine.  
2. Diagnosis  of type 1 or type 2 diabetes  mellitus  or secondary  forms  of diabetes  at 
Screening. Note : women with prior diagnoses of gestational diabetes during 
pregnancy only are eligible if they meet the other eligibility criteria.  
3. Any malignancy  not considered  cured  (except  basal  cell carcinoma  and squamous  cell 
carcinoma of the skin); a study participant is considered cured if there has been no 
evidence of cancer recurrence in the previous 5 years (from Screening). Anyone with 
any history of pancreatic CA will be excluded, even if it was resected and they were 
considered ‘cured’.  
4. Personal  or family  history  of MTC  or MEN2,  or study  participants  with suspected 
MTC per the investigator’s judgment.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 33  
 5. Acute  pancreatitis,  history  of repeated  episodes  of acute  pancreatitis,  or history  of 
chronic pancreatitis.  
6. Symptomatic  gallbladder  disease.  
7. Medical  history  or characteristics  suggestive  of genetic  or syndromic  obesity  or 
obesity induced by other endocrinological disorders (eg, Cushing Syndrome).  
8. History  of major  depressive  disorder  or history  of other  severe  psychiatric  disorders 
(eg, schizophrenia or bipolar disorder) within the last 2 years from screening.  
9. Known medical history of active liver disease, including chronic hepatitis B or C, 
primary biliary cirrhosis, alcoholic liver disease, primary sclerosing cholangitis, 
autoimmune  hepatitis,  overlap  syndrome,  or prior  known  drug-induced  liver injury.  
10. History  of HIV infection.  
11. Any lifetime history  of a suicide attempt.  
Prior/Concomitant Therapy  
12. Use of prescription  or nonprescription  drugs  and dietary  and herbal  supplements 
within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention (Refer to Section 6.9 for additional details).  
13. Use of any medications  that are: 
• Moderate  or strong  CYP3A4/5  and/or  CYP2C19  inhibitors  within  14 days or 5 
half-lives (whichever is longer),  
• Moderate  or strong  CYP3A  and/or  CYP2C19  inducers  within  14 days or 5 half- 
lives (whichever is longer),  
• Systemic  therapy  with inhibitors  of OATP  transporters  within  14 days or 5 half- 
lives (whichever is longer) prior to the first dose of study  intervention (Refer to 
Section 6.9 for additional details).  
14. Current  use of any prohibited  concomitant  medication(s)  or those  unwilling/unable  to 
use a permitted concomitant medication(s) (Refer to Section 6.9 for additional 
details).  
15. Any vaccine  (eg, COVID/influenza)  within  7 days prior  to the first dose of study 
intervention.  
Prior/Concurrent Clinical Study Experience:  
16. Previous  administration  with a GLP -1R agonist  (other  than PF-07081532)  within 
90 days preceding  the first dose of study  intervention  used in this study.  Previous  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 34  
 administration  with PF-07081532  within  30 days preceding  the first dose of study 
intervention used in this study.  
17. Previous  administration  with an investigational  product  (drug  or vaccine)  within  
30 days (or as determined  by the local  requirement)  or 5 half-lives  preceding  the first 
dose of study intervention used in this study (whichever is longer).  
Diagnostic  Assessments  (at Screening  unless  otherwise  indicated)  
18. A PHQ -9 score  ≥15 obtained  at Screening  or Day  -1 in Study.  
19. Response  of “yes”  to question  4 or 5, or on any suicidal  behavioral  question  on the 
C-SSRS at Screening or Day -1 in Study.  
20. A positive urine drug test. 
21. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at 
least 5 minutes  of supine  rest. BP should  be measured  in triplicate  and the average  of 
the 3 BP values should be used to determine the participant’s eligibility. Note : At 
Screening, the participant’s arm circumference should be measured (eg, using a 
flexible anthropometric tape) at the midpoint of the length of the upper arm, and the 
appropriate cuff selected and used throughout the study.  
22. Standard  12-lead ECG  that demonstrates  clinically  relevant  abnormalities  that may 
affect participant safety or interpretation of study results (eg, QTcF interval  
>450 msec, complete LBBB, signs of an acute or indeterminate age myocardial 
infarction  (documented  assessment),  ST-T interval  changes  suggestive  of myocardial 
ischemia, second - or third -degree AV block, or serious bradyarrhythmias or 
tachyarrhythmias).  
• If QTcF exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be 
repeated 2 more times and the average of the 3 QTcF or QRS values should be 
used to determine  the participant’s  eligibility.  Computer  interpreted  ECGs  should 
be overread by a physician experienced in reading ECGs before excluding 
participants.  
23. Participants  with ANY  of the following  abnormalities  in clinical  laboratory  tests at 
Screening, as assessed by the study specific laboratory and confirmed by a single 
repeat test, if deemed necessary:  
• HbA1c  ≥6.5%.  
• AST  or ALT  level  ≥1.25  × ULN.  
• Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's 
syndrome  may have  direct  bilirubin  measured  and would  be eligible  for this study 
provided the direct bilirubin level is ≤ ULN.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 35  
 • TSH  >1.5x  ULN  or <LLN.  
• Serum  calcitonin  >ULN.  
• Amylase  or lipase  >ULN.  
• Fasting  blood  glucose  ≥126  mg/dL.  
• Fasting  C-peptide  not within  normal  limit.  
• eGFR  <75 mL/min/1.73  m2 as calculated  by the CKD -EPI equation.  
24. Positive  testing  for HIV,  HBsAg,  HBcAb,  or HCVAb.  Study  participants  positive  for 
HCVAb  are to be excluded  unless  known  to have  been  treated  with a known  curative 
therapy and negative for HCV RNA. Anyone who has a history of HBV that is 
treated/cleared is excluded. Hepatitis B vaccination is allowed.  
25. A positive  SARS -CoV -2 test. 
Other  Exclusions:  at Screening  unless  indicated  
26. History of alcohol abuse or binge drinking and/or any other illicit drug use or 
dependence within 6 months of Screening. Binge drinking is defined as a pattern of 
5 (male)  and 4 (female)  or more  alcoholic  drinks  in about  2 hours.  As a general  rule, 
alcohol  intake  should  not exceed  14 units  per week  (1 unit = 8 ounces  (240 mL) beer, 
1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).  
27. Current  use of tobacco  or nicotine  containing  products  in excess  of the equivalent  of 
5 cigarettes per day.  
28. Blood  donation  (excluding  plasma  donations)  of approximately  1 pint (500 mL) or 
more within 60 days prior to dosing.  
29. History  of sensitivity  to heparin or heparin induced thrombocytopenia.  
30. Unwilling  or unable  to comply  with the criteria  or procedures  in the study.  
31. Investigator site staff directly involved in the conduct of the study and their family 
members,  site staff otherwise  supervised  by the investigator,  and sponsor  and sponsor 
delegate employees directly involved in the conduct of the study and their family 
members.  
5.3. Lifestyle Considerations  
The following  guidelines  are provided:  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 36  
 5.3.1.  Contraception  
The investigator or their designee, in consultation with the participant, will confirm that the 
participant is utilizing an appropriate method of contraception for the individual participant 
and their partner(s) from the permitted list of contraception methods (see Appendix 4 , 
Section  10.4.4 ) and will confirm  that the participant  has been  instructed  in its consistent  and 
correct use. At time points indicated in the SoA the investigator or designee will inform the 
participant of the need to use highly effective contraception consistently and correctly and 
document the conversation and the participant’s affirmation in the participant’s chart.  
Participants need to affirm their consistent and correct use of at least 1 of the selected 
methods  of contraception,  considering  that their risk for pregnancy  may have  changed  since 
the last visit.  
In addition, the investigator or designee will instruct the participant to call immediately  if the 
selected contraception method is discontinued and document the requirement to use an 
alternate protocol -specified method, including if the participant will no longer use abstinence 
as the selected  contraception  method,  or if pregnancy  is known  or suspected  in the participant 
or partner.  
5.3.2.  Meals  and Dietary  Restrictions  
• Participants must abstain from all food and drink (except water) at least 4 hours prior 
to any safety  laboratory  evaluations  and 10 hours  prior  to the collection  of the predose 
PK sample. The predose PK sample should be taken prior to consumption of the 
breakfast meal on Day 1 in Periods 1 and 2, and on Day 4 in Period 3.  
• Water is permitted until 1 hour prior to study  intervention administration. Water may 
be consumed  without  restriction  beginning  1 hour after dosing.  Noncaffeinated  drinks 
(except grapefruit or grapefruit -related citrus fruit juices —see below) may be 
consumed with meals and the evening snack.  
• During CRU confinement, participants should begin consumption of a standard 
breakfast (morning) approximately 30 minutes prior to dosing. The breakfast meal 
will be consumed over approximately  a 20-minute period, with the study  intervention 
administered  within  approximately  10 minutes  of completion  of the meal.  Participants 
will be encouraged to consume the entire meal.  
• Lunch  will be provided  approximately  4 hours  after dosing.  
• Dinner  will be provided  approximately  9 to 10 hours  after dosing.  
• An evening snack may  be permitted.  
• Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus  fruits  (eg, Seville  oranges,  pomelos,  fruit juices)  from  14 days prior  to the first 
dose of study intervention until collection of the final PK blood sample.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 37  
 • While participants are confined, their total daily nutritional composition should be 
approximately  55% carbohydrate,  30% fat, and 15% protein.  The daily  caloric  intake 
per participant should not exceed approximately 3200 kcal.  
5.3.3.  Caffeine,  Alcohol,  and Tobacco  
• Participants  will abstain  from  caffeine -containing  products  for 24 hours  prior  to the 
start of dosing until collection of the final PK sample.  
• Participants  will abstain  from  alcohol  for 24 hours  prior  (or as specified  above  for red 
wine) to admission to the CRU and continue abstaining from alcohol until collection 
of the final PK sample. Participants may undergo an alcohol breath test or blood 
alcohol test at the discretion of the investigator.  
• Participants  will abstain  from  the use of tobacco - or nicotine -containing  products  for 
24 hours prior to dosing and during confinement in the CRU.  
5.3.4.  Activity  
• Participants will abstain from strenuous exercise (eg, heavy lifting, weight training, 
calisthenics,  aerobics)  for at least 48 hours  prior  to each blood  collection  for clinical 
laboratory tests. Walking at a normal pace will be permitted;  
• In order to standardize the conditions on PK sampling days, participants will be 
required to refrain from lying down (except when required for BP, pulse rate, and 
ECG  measurements),  eating,  and drinking  beverages  other  than water  during  the first 
4 hours after dosing.  
5.4. Screen  Failures  
Screen  failures  are defined  as participants  who consent  to participate  in the clinical  study  but 
are not subsequently enrolled in the study. Screen failure data are collected and remain as 
source and are not reported on the CRF.  
Individuals  who do not meet  the criteria  for participation  in this study  (screen  failure)  may be 
rescreened.  
6. STUDY  INTERVENTION(S)  AND  CONCOMITANT  THERAPY  
Study  interventions  are all prespecified  investigational  and auxiliary  medicinal  products, 
medical devices, and other interventions (eg, surgical and behavioral) intended to be 
administered to the study participants during the study conduct.  
For the purposes  of this protocol,  study  intervention  refers  to PF-07081532,  itraconazole,  and 
cyclosporine.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 38  
 6.1. Study  Intervention(s)  Administered  
 
Study Intervention(s)  
Intervention  Name  PF-07081532  Itraconazole  Cyclosporine  
Arm  Name  
(group  of participants 
receiving a specific 
treatment or no 
treatment)  All participants  All participants  All participants  
Type  Drug  Drug  Drug  
Dose  Formulation  Tablet  Solution  Capsule  
Unit  Dose  Strength(s)  20 mg 10 mg/mL  100 mg 
Dosage  Level(s)  40 mg 200 mg (20 mL) 600 mg (6 × 100 mg) 
Route of 
Administration  Oral Oral Oral 
Use Substrate  Perpetrator  Perpetrator  
IMP  or AxMP  IMP AxMP  AxMP  
Sourcing  Provided  centrally  by the 
sponsor  Provided  locally  by the 
trial site  Provided  locally  by the 
trial site  
Packaging  and 
Labeling  Study intervention will 
be supplied by Pfizer to 
the CRU in bulk along 
with individual dosing 
containers,  as necessary, 
for unit dosing.  Commercially  available 
itraconazole will be 
supplied by the CRU.  Commercially  available 
cyclosporine will be 
supplied by the CRU.  
[Current/Former 
Name(s)  or Alias(es)]  N/A SPORANOX®  NEORAL®  
 
Study  Arm(s)  
Arm  Title  Period  1: PF-07081532  Period  2: Cyclosporine  + 
PF-07081532  Period  3: Itraconazole  + 
PF-07081532  
Arm  Type  No intervention  Experimental  (DDI)  Experimental  (DDI)  
Arm 
Description  Participants will 
receive PF -07081532 
as a single  40 mg dose 
on Day 1.  Participants will receive a single 
40 mg dose of PF-07081532  and a 
single  600 mg dose of cyclosporine  on 
Day 1.  Participants  will receive 
itraconazole 200 mg  
QD × 9 days plus a 
single 40 mg dose of 
PF-07081532  on Day 4. 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 39  
  
Study  Arm(s)  
Associated 
Intervention 
Labels  20 mg PF-07081532  
oral tablets  20 mg PF-07081532  oral tablets;  
Commercially  available  cyclosporine 
100 mg capsules  20 mg PF-07081532  oral 
tablets;  
Commercially  available 
itraconazole solution 
(10 mg/mL)  
 
PF-07081532  20 mg oral tablets  will be provided  by Pfizer  to the CRU  in bulk along  with 
individual dosing containers, as necessary, for unit dosing.  
Commercially  available itraconazole will be supplied by  the CRU. 
Commercially  available  cyclosporine  will be supplied  by the CRU.  
6.1.1.  Administration  
Following an overnight fast of at least 10 hours, participants will receive study intervention 
with the breakfast meal at approximately 0800 hours (±2 hours). Investigator site personnel 
will administer  PF-07081532,  itraconazole,  or cyclosporine  during  each period  (as applicable 
per SoA) with ambient temperature water to a total volume of approximately 240 mL. On 
coadministration day, participants may receive additional ambient temperature water up to 
100 mL, if needed. Details regarding meals on dosing days are provided in Section 5.3.2 . 
Participants  will swallow  the study  intervention  whole  and will not manipulate  or chew  (as 
relevant) the study intervention prior to swallowing.  
PF-07081532 must be administered within approximately 10 minutes of completion of the 
morning  meal.  PF-07081532  will be administered  first and itraconazole  or cyclosporine  will 
be administered within 5 minutes of PF -07081532 during the DDI assessment periods.  
In order to standardize the conditions on PK sampling days, all participants will be required 
to refrain from lying down (except when required for BP, pulse rate, and ECG 
measurements),  eating,  and drinking  beverages  other  than water  during  the first 4 hours  after 
dosing.  
6.2. Preparation,  Handling,  Storage,  and Accountability  
1. The investigator or designee must confirm that appropriate conditions (eg, 
temperature)  have  been  maintained  during  transit  for all study  interventions  received 
and any discrepancies  are reported  and resolved  before  use of the study  intervention.  
2. Only  participants  enrolled  in the study  may receive  study  intervention  and only 
authorized site staff may  supply, prepare, and/or administer study  intervention.  
3. All study interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated recording) area in accordance with the labeled 
storage  conditions  with access  limited  to the investigator  and authorized  site staff.  At 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 40  
 a minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request. Data for nonworking days must 
indicate  the minimum  and maximum  temperatures  since  previously  documented  upon 
return to business.  
4. Any excursions from the study intervention label storage conditions should be 
reported to Pfizer upon discovery  along with actions taken. The site should actively 
pursue  options  for returning  the study  intervention  to the labeled  storage  conditions, 
as soon as possible. Once an excursion is identified, the study intervention must be 
quarantined and not used until Pfizer provides permission to use the study 
intervention. Specific details regarding the excursion definition and information to 
report for each excursion will be provided to the site in the PCRU local/site 
procedures.  
5. Any storage  conditions  stated  in the SRSD  will be superseded  by the storage 
conditions stated on the label.  
6. Study  interventions  should  be stored  in their original  containers.  
7. The investigator,  institution,  head  of the medical  institution  (where  applicable),  or 
authorized site staff is responsible for study intervention accountability, 
reconciliation, and record maintenance (ie, receipt, reconciliation, and final 
disposition records), such as the IPAL or sponsor -approved equivalent. All study 
interventions will be accounted for using a study intervention accountability 
form/record.  
8. Further guidance and information for the final disposition of unused study 
interventions  are provided  in the PCRU’s  local/site  procedures.  All destruction  must 
be adequately documented. If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destroyed in 
compliance with applicable environmental regulations, institutional policy, and any 
special instructions provided by Pfizer.  
Upon  identification  of a product  complaint,  notify  the sponsor  within  1 business  day of 
discovery.  
6.2.1.  Preparation  and Dispensing  
Within  this protocol,  preparation  refers  to the investigator  site activities  performed  to make 
the study  intervention ready  for administration or dispensing to the participant by  qualified 
staff. Dispensing is defined as the provision of study  intervention, concomitant treatments, 
and accompanying information by qualified staff member(s) to a healthcare provider, 
participant, in accordance with this protocol. Local health authority regulations or 
investigator site guidelines may use alternative terms for these activities.  
Tablets/capsules/solution  will be prepared  at the CRU  in the individual  dosing  containers  by 
2 operators, 1 of whom is an appropriately qualified and experienced member of the study  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 41  
 staff (eg, physician, nurse, physician’s assistant, nurse practitioner, pharmacy 
assistant/technician,  or pharmacist).  The tablets,  capsules,  or solution  will be provided  in unit 
dose containers and labeled in accordance with Pfizer regulations and the clinical site’s 
labeling requirements.  
6.3. Assignment  to Study  Intervention  
The investigator’s  knowledge  of the treatment  should  not influence  the decision  to enroll  a 
particular participant or affect the order in which participants are enrolled.  
The investigator will assign participant numbers to the participants as they are screened for 
the study.  Pfizer  will provide  a randomization  schedule  to the investigator  and, in accordance 
with the randomization numbers, the participant will receive the study treatment regimen 
assigned to the corresponding randomization number.  
6.4. Blinding  
This is an open  label  study.  
6.5. Study  Intervention  Compliance  
When  the individual  dose for a participant  is prepared  from  a bulk supply,  the preparation  of 
the dose will be confirmed by a second qualified member of the study site staff.  
When  participants  are dosed  at the site, they will receive  study  intervention  directly  from  the 
investigator or designee, under medical supervision. The date and time of each dose 
administered  in the clinic  will be recorded  in the source  documents  and recorded  in the CRF. 
Study site personnel will examine each participant’s mouth to ensure that the study 
intervention was ingested.  
6.6. Dose Modification  
Dose  modification  will not be permitted  in this  study  for any  study  intervention.  
6.7. Continued  Access  to Study Intervention  After  the End of the Study  
No study intervention will be provided to participants at the end of their study participation. 
It is expected  that participants  will be treated  as required  with standard -of-care treatments,  as 
advised by their usual care physician.  
6.8. Treatment  of Overdose  
For this study, any  dose of PF-07081532  greater  than 1.6 g within  a 24-hour time period  will 
be considered an overdose. A single dose of 1.6 g is projected to result in exposure that will 
exceed that observed at the NOAEL in the pivotal 9 -month toxicology study in monkeys, 
after accounting for species differences in plasma protein binding.  
For this study,  overdose for  itraconazole  or cyclosporine  will be as per  the USPI  labels.13,14 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 42  
 There  is no specific  treatment  for an overdose  of PF-07081532.  Treatment  of overdose 
should consist of general supportive measures.  
In the event  of an overdose,  the investigator  should:  
1. Contact  the study  medical monitor within 24 hours.  
2. Closely  monitor  the participant  for any AEs/SAEs  and laboratory  abnormalities  as 
medically appropriate and at least until the next scheduled follow -up. 
3. Document  the quantity  of the excess  dose as well as the duration  of the overdose  in 
the CRF.  
4. Overdose is reportable to Pfizer Safety  only when associated with an SAE.  
5. Obtain  a blood  sample  for PK analysis  within  1 day from  the date of the last dose of 
study  intervention if requested by  the study  medical monitor (determined on a case - 
by-case basis).  
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation  with the study  medical  monitor  as needed  based  on the clinical  evaluation  of the 
participant.  
6.9. Prior  and Concomitant  Therapy  
Study  participants  will abstain  from  all concomitant  treatments,  except  for the treatment  of 
AEs, as described in the Exclusion Criteria section of this protocol.  
Use of prescription or nonprescription drugs and dietary and herbal supplements are 
prohibited  within  7 days or 5 half-lives  (whichever  is longer)  prior  to the first dose of study 
intervention.  
Sytemic  therapy  with moderate  or strong  CYP3A4/5  and/or  CYP2C19  inhibitors  or inducers 
within 14 days or 5 half -lives (whichever is longer) prior to the first dose of study 
intervention are prohibited. Systemic therapy with inhibitors of OATP transporters within  
14 days or 5 half -lives (whichever is longer) prior to the first dose of study intervention are 
prohibited.  
Use of a GLP -1R agonist is prohibited within 90 days prior to the first dose of study 
intervention,  with the exception  of PF-07081532,  which  is prohibited  within  30 days prior  to 
the first dose of study drug.  
Limited  use of nonprescription  medications  that are not believed  to affect  participant  safety 
or the overall results of the study may be permitted on a case -by-case basis following 
approval by the sponsor. Acetaminophen/paracetamol may be used at doses of ≤1 g/day.  
Anti-emetics  (eg, prochlorperazine,  promethazine,  ondansetron)  may be administered  at the 
investigator’s discretion with notification to the sponsor and entry in the CRF.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 43  
 Sites  are encouraged  to contact  the sponsor  should  there  be questions  as to whether  a 
medication is permitted or prohibited.  
Implantable  progestogen  or intrauterine  hormone  releasing  system  only are allowed  to be 
used in participants who are WOCBP (see Appendix 4 ). 
Females using hormonal contraceptives that do not meet the requirements of this study or 
who are taking hormone replacement therapy may be eligible to participate in this study if 
they are willing to discontinue therapy at least 28 days prior to the first dose of study 
treatment  and remain  off hormonal  therapy  for the duration  of the study.  Depo -Provera® must 
be discontinued at least 6 months prior to the first dose of study treatment.  
All concomitant  treatments  taken  during  the study  must  be recorded  with indication,  daily 
dose, and start and stop dates of administration. All participants will be questioned about 
concomitant treatment at each clinic visit.  
Treatments taken within 28 days before the first dose of study intervention will be 
documented  as a prior  treatment.  Treatments  taken  after the first dose of study  intervention 
will be documented as concomitant treatments.  
6.9.1.  Rescue Medicine  
There  is no rescue  therapy  to reverse  the AEs observed  with PF-07081532;  standard  medical 
supportive care must be provided to manage the AEs, including administration of 
carbohydrates to treat HAEs (see Section 8.3.6 ). 
6.9.1.1.  Management  of Nausea  and Vomiting  
Nausea and vomiting have been reported with administration of GLP -1R agonists and also 
with administration of PF -07081532 (see Section 2.2.4 ). Study participants complaining of 
nausea may be managed conservatively with bed rest and/or fluid management at the 
discretion of the investigator. If nausea and vomiting are not amenable to conservative 
management, anti -emetics (eg, prochlorperazine, promethazine, ondansetron) may be 
administered  at the investigator’s  discretion  with notification  to the sponsor  and entry  in the 
CRF.  
7. DISCONTINUATION  OF STUDY  INTERVENTION  AND  PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  
7.1. Discontinuation  of Study  Intervention  
It may  be necessary  for a participant  to permanently  discontinue  study  intervention.  Reasons 
for permanent discontinuation of study intervention include the following:  
• Criteria  for a potential  Hy’s law  case are  met (see  Appendix 6). 
• Intent  to become pregnant or  pregnancy  confirmed by  serum  -hCG testing.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 44  
 • Safety  or tolerability  concern  arises,  in particular,  if not responsive  to symptomatic 
management, dosing with study intervention may be stopped in an individual 
participant at investigator discretion.  
• Based  on mental  health  assessment  as outlined  in Section  8.3.8 , should  be 
discontinued from dosing at investigator discretion.  
• Positive  SARS -CoV -2 Test.  
If the criteria  for permanent  discontinuation  are met, the site should  notify  the sponsor 
Medical Monitor or sponsor Clinician.  
Note  that discontinuation  of study  intervention  does not represent  withdrawal  from  the study. 
If study intervention is permanently discontinued, the participant should remain in the study 
to be evaluated for safety. See the SoA for data to be collected at the time of discontinuation 
of study intervention and follow -up for any further evaluations that need to be completed.  
In the event of discontinuation of study intervention, it must be documented on the 
appropriate CRF/in the medical records whether the participant is discontinuing further 
receipt  of study  intervention  or also from  study  procedures,  post-treatment  study  follow -up, 
and/or future collection of additional information.  
7.1.1.  Potential  Cases  of Acute  Kidney Injury  
Abnormal  values  in Scr concurrent  with presence  or absence  of increase  in BUN  that meet 
the criteria  below,  in the absence  of other  causes  of kidney  injury,  are considered  potential 
cases of acute kidney injury and should be considered important medical events.  
An increase  of ≥0.3 mg/dL  (or ≥26.5  µmol/L)  in Scr level  relative  to the participant’s  own 
baseline measurement should trigger another assessment of Scr as soon as practically 
feasible, preferably within 48 hours from awareness.  
If the second  assessment (after  the first  observations of ≥0.3 mg/dL  [or ≥26.5 µmol/L] in Scr 
relative  to the participant’s  own baseline  measurement)  is ≥0.4 mg/dL  (or ≥35.4  µmol/L),  the 
participant should be discontinued from the study and adequate, immediate, supportive 
measures taken to correct apparent acute kidney injury.  
Participants should return to the investigator site and be evaluated as soon as possible, 
preferably within 48 hours from awareness of the second assessment confirming abnormal 
Scr result. This evaluation should include laboratory tests, detailed history, and physical 
assessment. In addition to repeating Scr, laboratory tests should include serum BUN, serum 
creatine kinase, and serum electrolytes (including at a minimum potassium, sodium, 
phosphate/phosphorus, and calcium), in addition to urinary dipstick, urine microscopic 
examination, and urinary indices. All cases confirmed on repeat testing as meeting the 
laboratory  criteria  for acute  kidney  injury,  with no other  cause(s)  of laboratory  abnormalities 
identified,  should  be considered  potential  cases  of drug-induced  kidney  injury  irrespective  of 
availability of all the results of the investigations performed to determine etiology of the  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 45  
 abnormal  Scr. If ≥2 healthy  participants  in a given  period  are noted  to have  2 consecutive  Scr 
results of ≥0.3 mg/dL (or ≥26.5 µmol/L), an assessment of whether the finding may be 
considered an adverse drug reaction should be undertaken.  
7.2. Participant  Discontinuation/Withdrawal  From  the Study  
A participant  may withdraw  from  the study  at any time at their own request.  Reasons  for 
discontinuation from the study include the following: safety, behavioral, compliance, 
administrative reasons, and/or if the study is terminated by the sponsor.  
At the time of discontinuing  from  the study,  if possible,  an early  discontinuation  visit should 
be conducted. See the SoA for assessments to be collected at the time of study 
discontinuation and follow -up and for any further evaluations that need to be completed.  
The early  discontinuation  visit applies  only to participants  who are enrolled/randomized  and 
then are prematurely  withdrawn  from  the study.  Participants  should  be questioned  regarding 
their reason for withdrawal.  
The participant  will be permanently  discontinued  from  the study  intervention  and the study  at 
that time.  
If a participant withdraws from the study, they may request destruction of any remaining 
samples  taken  and not tested,  and the investigator  must  document  any such requests  in the 
site study records and notify the sponsor accordingly.  
If the participant  withdraws  from  the study  and also withdraws  consent  (see Section  7.2.1) 
for disclosure of future information, no further evaluations will be performed and no 
additional data will be collected. The sponsor may retain and continue to use any data 
collected before such withdrawal of consent.  
7.2.1.  Withdrawal of  Consent  
Participants  who request  to discontinue  receipt  of study  intervention  will remain  in the study 
and must continue to be followed for protocol -specified follow -up procedures. The only 
exception  to this is when  a participant  specifically  withdraws  consent  for any further  contact 
with them or persons previously authorized by the participant to provide this information.  
Participants should notify the investigator in writing of the decision to withdraw consent 
from future follow -up, whenever possible. The withdrawal of consent should be explained in 
detail in the medical records by the investigator, as to whether the withdrawal is only from 
further  receipt  of study  intervention  or also from  study  procedures  and/or  posttreatment  study 
follow -up, and entered on the appropriate CRF page. In the event that vital status (whether 
the participant is alive or dead) is being measured, publicly available information should be 
used to determine vital status only as appropriately directed in accordance with local law.  
7.3. Lost  to Follow -up 
A participant  will be considered  lost to follow -up if the participant  repeatedly  fails to return 
for scheduled visits and is unable to be contacted by the study site.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 46  
 The following  actions  must  be taken  if a participant  fails to attend  a required  study  visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible. Counsel the participant on the importance of maintaining the 
assigned  visit schedule  and ascertain  whether  the participant  wishes  to and/or  should 
continue in the study;  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make  every  effort  to regain  contact  with the participant  (where  possible,  3 telephone 
calls and, if necessary, a certified letter to the participant’s last known mailing 
address  or local equivalent methods). These contact attempts  should be documented 
in the participant’s medical record;  
• Should  the participant  continue  to be unreachable,  the participant  will be considered 
to have withdrawn from the study.  
8. STUDY ASSESSMENTS AND  PROCEDURES  
8.1. Administrative  Procedures  
The investigator  (or an appropriate  delegate  at the investigator  site) must  obtain  a signed  and 
dated ICD before performing any study -specific procedures.  
Study  procedures  and their timing  are summarized  in the SoA. Protocol  waivers  or 
exemptions are not allowed.  
Adherence  to the study  design  requirements,  including  those  specified  in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential 
participants  meet  all eligibility  criteria.  The investigator  will maintain  a screening  log to 
record  details  of all participants  screened  and to confirm  eligibility  or record  reasons  for 
screening failure, as applicable.  
Participants will be screened within 28 days prior to administration of the study  intervention 
to confirm that they meet the study population criteria for the study. If the time between 
screening and dosing exceeds 28 days as a result of unexpected delays (eg, delayed drug 
shipment),  then participants  do not require  rescreening  if the laboratory  results  obtained  prior 
to first dose administration meet eligibility criteria.  
A participant  who qualified  for this protocol  but did not enroll  from  an earlier  cohort/group 
may be used in a subsequent cohort/group without rescreening, provided laboratory  results 
obtained prior to the first dose administration meet eligibility criteria for this study. In 
addition, other clinical assessments or specimen collections, eg, retained research samples, 
may be used without repeat collection, as appropriate.  
Every effort should be made to ensure that protocol -required tests and procedures are 
completed  as described.  However,  it is anticipated  that from  time to time there  may be 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 47  
 circumstances outside the control of the investigator that make it unfeasible to perform the 
test. In these cases, the investigator must take all steps necessary to ensure the safety and 
well-being of the participant. When a protocol -required test cannot be performed, the 
investigator  will document  the reason  for the missed  test and any corrective  and preventive 
actions that they have taken to ensure that required processes are adhered to as soon as 
possible. The study team must be informed of these incidents in a timely manner.  
If an IV catheter  is utilized  for blood  sample  collections,  ECGs  and vital sign assessments 
(pulse rate and BP) should be collected prior to the insertion of the catheter.  
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment  instructions  and contact  information  will be provided  to the investigator  site prior 
to initiation of the study.  
The total blood sampling volume for individual participants in this study is approximately 
200 mL. The actual collection times of blood sampling may change. Additional blood 
samples may  be taken for safety assessments at times specified by  Pfizer, provided the total 
volume  taken  during  the study  does not exceed  550 mL during  any period  of 56 consecutive 
days.  
To prepare  for study  participation,  participants  will be instructed  on the information  in the 
Lifestyle Considerations and Prior and Concomitant Therapy sections of the protocol.  
8.2. Efficacy  Assessments  
Efficacy  is not evaluated in this study.  
8.3. Safety  Assessments  
Planned  time points  for all safety  assessments  are provided  in the SoA. Unscheduled  safety 
measurements may  be obtained at any  time during the study  to assess any  perceived safety 
issues.  
8.3.1.  Physical Examinations  
A complete  physical  examination  will include,  at a minimum,  head,  ears, eyes,  nose,  mouth, 
skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and 
neurological systems.  
A brief  physical  examination  will include,  at a minimum,  assessments  of general  appearance, 
the respiratory and cardiovascular systems, and participant -reported symptoms.  
Physical  examinations  may be conducted  by a physician,  trained  physician’s  assistant,  or 
nurse practitioner as acceptable according to local regulation.  
Height  and weight  will also be measured  and recorded  as per the SoA. For measuring  weight, 
a scale with appropriate range and resolution is used and must be placed on a stable, flat 
surface. Participants must remove shoes, bulky layers of clothing, and jackets so that only  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 48  
 light clothing  remains.  They  must  also remove  the contents  of their pockets  and remain  still 
during measurement of weight.  
Physical  examination  findings  collected  during  the study  will be considered  source  data and 
will not be required to be reported, unless otherwise noted. Any untoward physical 
examination findings that are identified during the active collection period and meet the 
definition of an AE or SAE ( Appendix 3 ) must be reported according to the processes in 
Section 8.4.1 to Section 8.4.3 . 
8.3.2.  Vital Signs  
8.3.2.1.  Blood  Pressure  and Pulse  Rate  
Supine  BP will be measured  with the participant’s  arm supported  at the level  of the heart  and 
recorded to the nearest mm Hg after approximately 5 minutes of rest. The same arm 
(preferably the dominant arm) will be used throughout the study. Participants should be 
instructed not to speak during measurements. If triplicate measurements are obtained, they 
should be collected approximately 2 minutes apart.  
The same  properly  sized  and calibrated  BP cuff will be used to measure  BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manually, pulse rate will be measured in the brachial/radial artery for at least  
30 seconds.  When  the timing  of these  measurements  coincides  with a blood  collection,  BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.  
Additional  collection  times,  or changes  to collection  times,  of BP and pulse  rate will be 
permitted, as necessary, to ensure appropriate collection of safety data.  
Any untoward  vital sign findings  that are identified  during  the active  collection  period  and 
meet the definition of an AE or SAE ( Appendix 3 ) must be reported according to the 
processes in Section 8.4.1 to Section 8.4.3 . 
8.3.2.2.  Temperature  
Temperature  will be measured  orally  at Screening.  No eating,  drinking,  or smoking  is 
allowed for 15 minutes prior to the measurement.  
8.3.3.  Electrocardiograms  
Standard 12 -lead ECGs utilizing limb leads (with a 10 -second rhythm strip) should be 
collected at times specified in the SoA of this protocol using an ECG methodology that 
automatically calculates the HR and measures PR interval, QT interval, QTcF, and QRS 
complex.  All scheduled  ECGs  should  be performed  after the participant  has rested  quietly  for 
at least 5 minutes in a supine position.  
To ensure  safety  of the participants,  a qualified  individual  at the investigator  site will make 
comparisons to baseline measurements. Additional ECG monitoring will occur if a) a 
postdose QTcF interval is increased by  ≥60 ms from the baseline and is >450 ms; or b) an 
absolute QT value is ≥500 ms for any scheduled ECG. If either of these conditions occurs,  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 49  
 then 2 additional  ECGs  will be collected  approximately  2 to 4 minutes  apart  to confirm  the 
original measurement. If the QTcF values from these repeated ECGs remain above the 
threshold value, then a single ECG must be repeated at least hourly until QTc values from 
2 successive ECGs fall below the threshold value that triggered the repeat measurement.  
If a) a postdose QTcF interval remains ≥60 ms from the baseline and is >450 ms; or b) an 
absolute  QT value  is ≥500  ms for any scheduled  ECG  for greater  than 4 hours  (or sooner,  at 
the discretion  of the investigator);  or c) QTcF  value  get progressively  longer,  the participant 
should undergo continuous ECG monitoring. A cardiologist should be consulted if QTcF 
values do not return to less than the criteria listed above after 8 hours of monitoring (or 
sooner, at the discretion of the investigator).  
In some cases, it may be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as  contributing to the ECG  abnormality. It is  important that leads  be placed  in the 
same  positions  each time in order  to achieve  precise  ECG  recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may not be necessary if a 
qualified medical provider’s interpretation determines that the QTcF values are in the 
acceptable range.  
ECG  values  of potential  clinical  concern  are listed  in Appendix 8. 
8.3.4.  Clinical  Safety  Laboratory  Assessments  
See Appendix  2 for the list of clinical  safety  laboratory  tests to be performed  and the SoA for 
the timing and frequency. All protocol required laboratory assessments, as defined in 
Appendix 2 , must be conducted in accordance with the laboratory manual and the SoA. 
Unscheduled clinical laboratory  measurements may  be obtained at any  time during the study 
to assess any perceived safety issues.  
The investigator must review the laboratory report, document this review, and record any 
clinically significant changes occurring during the study in the AE section of the CRF. 
Clinically  significant abnormal laboratory  test findings are those that are not associated with 
the underlying  disease,  unless  judged  by the investigator  to be more  severe  than expected  for 
the participant’s condition.  
All laboratory tests with values considered clinically significant and abnormal during 
participation  in the study  or within  28 days after  the last dose of study  intervention  should  be 
repeated until the values return to normal or baseline or are no longer considered clinically 
significant by the investigator or study medical monitor.  
If such values  do not return  to normal/baseline  within  a period  of time judged  reasonable  by 
the investigator, the etiology should be identified and the sponsor notified.  
See Appendix  6 for suggested  actions  and follow -up assessments  in the event  of potential 
DILI.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 50  
 See Appendix  7 for instructions  for laboratory  testing  to monitor  kidney  function  and 
reporting laboratory test abnormalities.  
Participants may  undergo random urine drug testing at the discretion of the investigator. 
Drug  testing  conducted  prior  to dosing  must  be negative  for participants  to receive  study 
intervention.  
8.3.5.  COVID -19 Specific  Assessments  
Participants  will be tested  for COVID -19 infection  by PCR  at admission  to the clinic  for 
confinement,  and if they  develop  COVID -19 -like symptoms.  Additional  testing  may be 
required by local regulations or by the PI.  
8.3.6.  Management  of Hypoglycemia  
While  hypoglycemia  is not expected  in the study  participants,  fasting  blood  glucose  will be 
measured as part of laboratory assessment per the SoA. In addition, as a precaution, 
participants will be monitored for the signs and symptoms associated with hypoglycemia.  
Any episode of hypoglycemia must be captured on the HAE CRF with specific details 
captured  on the HAE  Form  CRF.  For the definition  of a hypoglycemic  episode  and severity 
categorization see Section 8.3.6.1 below.  
For medical management of hypoglycemia, the investigator may  administer oral 
carbohydrate,  glucagon,  or IV glucose  according  to his or her medical  judgment.  
8.3.6.1.  Definition  and Severity  of Categorization  of Hypoglycemic  Adverse  Event  
The investigator  must  assess  the glucose  values  reported  by the central/local  laboratory,  as 
well as any signs or symptoms reported by the study participant.  
HAE  is defined  as one of the following:24 
a. Asymptomatic  hypoglycemia:  An event  not accompanied  by typical  symptoms  of 
HAE but a glucose value of <70 mg/dL (3.9 mmol/L) using either glucometer 
(fingerstick blood glucose) at the study site or sponsor -identified central/local 
laboratory (blood glucose).  
b. Documented symptomatic hypoglycemia: An event during which typical symptoms 
of HAE are accompanied with a glucose value of <70 mg/dL (3.9 mmol/L), using 
glucometer at the study site or sponsor identified central/local laboratory, and the 
clinical  picture  includes  prompt  resolution  with food intake,  subcutaneous  glucagon, 
or IV glucose.  
c. Probable symptomatic hypoglycemia: An event during which symptoms of HAE are 
not accompanied  by a glucose  determination  but was presumably  caused  by a glucose 
concentration of <70 mg/dL (3.9 mmol/L), and the clinical picture includes prompt 
resolution with food intake, subcutaneous glucagon, or IV glucose.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 51  
 Each  episode  of HAE  must  be categorized  with respect  to severity.  In order  to characterize 
the event as severe, all 3 criteria below must be met:  
1. The participant  was unable  to treat him/herself.  Neurologic  impairment,  and not the 
age of the participant, is the explanation for why the participant could not treat 
him/herself and required the assistance of another person.  
2. The participant  exhibited  at least 1 of the following  neurological  symptoms:  
• Memory  loss. 
• Confusion.  
• Uncontrolled  behavior.  
• Irrational  behavior.  
• Unusual difficulty  in awakening.  
• Suspected  seizure.  
• Seizure.  
• Loss  of consciousness.  
3. Either:  
• If blood  glucose  was measured  and was ≤54 mg/dL  (2.7 mmol/L)  using 
glucometer (or central/local laboratory) or  
• If blood  glucose  was not measured,  the clinical  manifestations  were  reversed  by 
oral carbohydrates, subcutaneous glucagon, or IV glucose.  
Events  that do not meet  all the criteria  above  for severe  HAE  are characterized  as mild or 
moderate in severity . 
8.3.6.2.  Glucometer Monitoring of Glucose  
Monitoring  of FSBG  using  glucometer  measurements  is not required  per protocol  but may be 
obtained if the investigator or participant notes symptoms of hypoglycemia.  
If obtained,  FSBG  readings  will be maintained  at the CRU  in source  documents,  and only the 
glucose results from the laboratory will be reported in the study database.  
If an FSBG  result  is ≤70 mg/dL,  a second  FSBG  should  be obtained  to confirm  the glucose 
value, in addition to a venous sample that will be sent to the clinical laboratory for 
confirmation.  If the value  from  this second  FSBG  is also ≤70 mg/dL,  the second  value  will 
be recorded as a hypoglycemic AE. FSBG will continue to be monitored until the glucose  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 52  
 value  returns  to >70 mg/dL.  Samples  may be taken  more  frequently  if deemed  necessary  by 
the investigator.  
8.3.7.  Pregnancy  Testing  
A serum pregnancy test is required at Screening. Following screening, pregnancy tests may 
be urine or serum tests, and must have a sensitivity of at least 25 mIU/mL. Pregnancy tests 
will be performed  in WOCBP  at the times  listed  in the SoA. Following  a negative  pregnancy 
test result  at screening,  appropriate  contraception  must  be commenced  and a second  negative 
pregnancy test result will be required at the baseline visit prior to the participant’s receiving 
the study intervention. Pregnancy tests will also be done whenever 1 menstrual cycle is 
missed during the active treatment period (or when potential pregnancy is otherwise 
suspected)  and at the end of the study  prior  to discharge  on Period  3 Day 10. Pregnancy  tests 
may also be repeated if requested by IRBs/ECs or if required by local regulations. If a urine 
test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required. In such cases, the participant must be excluded if the serum pregnancy result is 
positive.  
8.3.8.  Suicidal  Ideation  and Behavior  Risk  Monitoring  
8.3.8.1.  Columbia Suicide Severity Rating Scale  
The C -SSRS is an interview -based rating scale to systematically assess suicidal ideation and 
suicidal  behavior.25 The “baseline/screening”  version  of the C-SSRS26 will be administered  at 
Screening and Day  -1 in study. Participants who respond “yes” to Question 4 or 5 (indicating 
suicidal ideation), or to any suicidal behavioral question on the C -SSRS at screening or  
Day -1 will not be permitted in the study (see Section 5.2 ). The “since last visit” version of 
the C-SSRS27 will be administered  at the time points  specified  in the SoA. The C-SSRS  will 
be administered by study site staff who have completed training in its administration.  
8.3.8.2.  Patient  Health  Questionnaire -9 (PHQ -9) 
The PHQ9 -9 is a 9 item self -report scale for the assessment of depressive symptoms.28 The 
PHQ -9 will be completed by participants and reviewed by site staff at the pre -defined time 
points  outlined  in the SoA. A PHQ -9 score  of ≥15 at Screening  or Day -1 indicates  clinically 
significant depression and serves as an exclusion criterion for this study (see Section 5.2 ). 
8.3.8.3.  Referral  to a Mental  Health  Professional  
A participant  should  be referred  to a MHP  for the following  reasons:  
• Response  of “yes”  to question  4 or 5, or on any suicidal  behavioral  question  on the 
C-SSRS.  
• A score  of ≥10 on the PHQ -9. 
• In the investigator’s  judgment  a risk assessment  or exclusion  is required.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 53  
 A clinically  qualified  MHP  is an MHP  with appropriate  training  in the assessment  of suicide 
risk, according to local clinical practice standards and regulations, who would normally 
evaluate the risk for suicidal ideation and behavior in a patient.  
Participants who have recurrent suicidal ideation or behavior during the study should be 
discontinued from the study  and treated appropriately. If a  study  participant  endorses  a 4 or 5 
on the ideation subscale or any behavioral item of the C -SSRS on 2 or more occasions and is 
confirmed  to have  active  suicidal  ideation  or behavior  on both occasions  by a risk assessment 
conducted by a qualified MHP, then the participant should be discontinued from the study 
and treated appropriately.  
Participants  who meet  criteria  for referral  to a MHP  but refuse  evaluation  and/or  treatment  by 
a MHP, must be assessed by the investigator to determine if the participant should be 
discontinued from dosing or from the study.  
8.4. Adverse  Events,  Serious  Adverse  Events,  and Other  Safety  Reporting  
The definitions  of an AE and  an SAE  can be found  in Appendix 3. 
AEs may arise from symptoms or other complaints reported to the investigator by the 
participant (or, when appropriate, by a caregiver, surrogate, or the participant’s legally 
authorized  representative),  or they may arise  from  clinical  findings  of the investigator  or 
other healthcare providers (clinical signs, test results, etc).  
The investigator  and any qualified  designees  are responsible  for detecting,  documenting,  and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether the 
event meets the criteria for classification as an SAE or caused the participant to discontinue 
the study intervention (see Section 7.1 ). 
During  the active  collection  period  as described  in Section  8.4.1,  each participant  will be 
questioned about the occurrence of AEs in a nonleading manner.  
In addition,  the investigator  may be requested  by Pfizer  Safety  to obtain  specific  follow -up 
information in an expedited fashion.  
8.4.1.  Time  Period  and Frequency  for Collecting  AE and SAE  Information  
The time period for actively eliciting and collecting AEs and SAEs (“active collection 
period”)  for each participant  begins  from  the time the participant  provides  informed  consent, 
which is obtained before undergoing any study -related procedure and/or receiving study 
intervention), through and including a minimum of 28 calendar days after the last 
administration of the study intervention.  
Follow -up by the investigator  continues  throughout  the active  collection  period  and until the 
AE or SAE or its sequelae resolve or stabilize at a level acceptable to the investigator.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 54  
 When  a clinically  important  AE remains  ongoing  at the end of the active  collection  period, 
follow -up by the investigator continues until the AE or SAE or its sequelae resolve or 
stabilize at a level acceptable to the investigator and Pfizer concurs with that assessment.  
For participants  who are screen  failures,  the active  collection  period  ends when  screen  failure 
status is determined.  
If the participant  withdraws  from  the study  and also withdraws  consent  for the collection  of 
future information, the active collection period ends when consent is withdrawn.  
If a participant  permanently  discontinues  or temporarily  discontinues  study  intervention 
because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE 
reported using the CT SAE Report Form.  
Investigators are not obligated to actively seek information on AEs or SAEs after the 
participant  has concluded  study  participation.  However,  if the investigator  learns  of any SAE, 
including a death, at any time after a participant has completed the study, and they consider 
the event to be reasonably related to the study intervention, the investigator must promptly 
report the SAE to Pfizer using the CT SAE Report Form.  
8.4.1.1.  Reporting  SAEs  to Pfizer Safety  
All SAEs occurring in a participant during the active collection period as described in 
Section  8.4.1  are reported  to Pfizer  Safety  on the CT SAE  Report  Form  immediately  upon 
awareness and under no circumstance should this exceed 24 hours, as indicated in 
Appendix 3 . The investigator will submit any updated SAE data to the sponsor within  
24 hours  of its being  available.  
8.4.1.2.  Recording  Nonserious  AEs and SAEs  on the CRF  
All nonserious AEs and SAEs occurring in a participant during the active collection period, 
which  begins  after obtaining  informed  consent  as described  in Section  8.4.1 , will be recorded 
on the AE section of the CRF.  
The investigator  is to record  on the CRF  all directly  observed  and all spontaneously  reported 
AEs and SAEs reported by the participant.  
As part of ongoing safety reviews conducted by the sponsor, any nonserious AE that is 
determined  by the sponsor  to be serious  will be reported  by the sponsor  as an SAE.  To assist 
in the determination of case seriousness, further information may be requested from the 
investigator to provide clarity and understanding of the event in the context of the clinical 
study.  
Reporting  of AEs and SAEs  for participants  who fail screening  are subject  to the CRF 
requirements as described in Section 5.4 . 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 55  
 8.4.2.  Method  of Detecting  AEs and SAEs  
The method  of recording,  evaluating,  and assessing  causality  of AEs and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 . 
Care  will be taken  not to introduce  bias when  detecting  AEs and/or  SAEs.  Open -ended  and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.4.3.  Follow -Up of AEs and SAEs  
After the initial AE or SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain  adequate  information  until resolution,  stabilization,  the event  is otherwise  explained, 
or the participant is lost to follow -up (as defined in Section 7.3 ). 
In general,  follow -up information  will include  a description  of the event  in sufficient  detail  to 
allow for a complete medical assessment of the case and independent determination of 
possible causality. Any information relevant to the event, such as concomitant medications 
and illnesses, must be provided. In the case of a participant death, a summary of available 
autopsy findings must be submitted as soon as possible to Pfizer Safety.  
Further  information  on follow -up procedures  is provided  in Appendix 3. 
8.4.4.  Regulatory  Reporting  Requirements  for SAEs  
Prompt notification by the investigator to the sponsor of an SAE is essential so that legal 
obligations  and ethical  responsibilities  toward  the safety  of participants  and the safety  of a 
study intervention under clinical investigation are met.  
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies  about  the safety  of a study  intervention  under  clinical  investigation.  The 
sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, IRBs/ECs, and investigators.  
Investigator  safety  reports  must  be prepared  for SUSARs  according  to local  regulatory 
requirements and sponsor policy and forwarded to investigators as necessary.  
An investigator who receives SUSARs or other specific safety information (eg, summary  or 
listing  of SAEs)  from  the sponsor  will review  and then file it along  with the SRSD(s)  for the 
study and will notify the IRB/EC, if appropriate, according to local requirements.  
8.4.5.  Environmental  Exposure,  Exposure  During  Pregnancy  or Breastfeeding,  and 
Occupational Exposure  
Environmental exposure, occurs when a person not enrolled in the study as a participant 
receives  unplanned  direct  contact  with or exposure  to the study  intervention.  Such  exposure 
may or may  not lead to the occurrence of an AE or SAE. Persons at risk for environmental  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 56  
 exposure  include  healthcare  providers,  family  members,  and others  who may be exposed.  An 
environmental exposure may include EDP, EDB, and occupational exposure.  
Any such exposures  to the study  intervention  under  study  are reportable  to Pfizer  Safety 
within 24 hours of investigator awareness.  
8.4.5.1.  Exposure During Pregnancy  
An EDP  occurs  if: 
• A female  participant  is found  to be pregnant  while  receiving  or after discontinuing 
study intervention . 
• A male  participant  who is receiving  or has discontinued  study  intervention 
inseminates a female partner.  
• A female  nonparticipant  is found  to be pregnant  while  being  exposed  or having  been 
exposed to study intervention because of environmental exposure. Below are 
examples of environmental EDP:  
• A female  family  member  or healthcare  provider  reports  that she is pregnant  after 
having been exposed to the study intervention by ingestion.  
• A male  family  member  or healthcare  provider  who has been  exposed  to the study 
intervention by ingestion then inseminates his female partner prior to or around 
the time of conception.  
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s 
awareness,  irrespective  of whether  an SAE  has occurred.  The initial  information  submitted 
should include the anticipated date of delivery (see below for information related to 
termination of pregnancy).  
• If EDP occurs in a participant/participant’s partner, the investigator must report this 
information  to Pfizer  Safety  on the CT SAE  Report  Form  and an EDP  Supplemental 
Form, regardless of whether an SAE has occurred. Details of the pregnancy will be 
collected after the start of study intervention and until 28 days after the last dose.  
• If EDP  occurs  in the setting  of environmental exposure, the investigator must report 
information  to Pfizer  Safety  using  the CT SAE  Report  Form  and EDP  Supplemental 
Form. Since the exposure information does not pertain to the participant enrolled in 
the study, the information is not recorded on a CRF; however, a copy of the 
completed CT SAE Report Form is maintained in the investigator site file.  
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP  reports  with an unknown  outcome.  The investigator  will follow  the pregnancy  until 
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a 
followup to the initial EDP Supplemental Form. In the case of a live birth, the structural  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 57  
 integrity  of the neonate  can be assessed  at the time of birth.  In the event  of a termination,  the 
reason(s) for termination should be specified and, if clinically possible, the structural 
integrity of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomaly and the findings are 
reported).  
Abnormal  pregnancy  outcomes  are considered  SAEs.  If the outcome  of the pregnancy  meets 
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal 
demise, neonatal death, or congenital anomaly in a live -born baby, a terminated fetus, an 
intrauterine fetal demise, or a neonatal death), the investigator should follow the procedures 
for reporting SAEs. Additional information about pregnancy outcomes that are reported to 
Pfizer Safety as SAEs follows:  
• Spontaneous  abortion  including  miscarriage  and missed  abortion  should  be reported 
as an SAE;  
• Neonatal  deaths  that occur  within  1 month  of birth  should  be reported,  without  regard 
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the study intervention.  
Additional information regarding the EDP may be requested by the sponsor. Further 
follow -up of birth outcomes will be handled on a case -by-case basis (eg, follow -up on 
preterm infants to identify developmental delays). In the case of paternal exposure, the 
investigator  will provide  the participant  with the Pregnant  Partner  Release  of Information  
Form to deliver to his partner. The investigator must document in the source documents that 
the participant  was given  the Pregnant  Partner  Release  of Information  Form  to provide  to his 
partner.  
8.4.5.2.  Exposure During Breastfeeding  
An EDB  occurs  if: 
• A female  participant  is found  to be breastfeeding  while  receiving  or after 
discontinuing study intervention.  
• A female  nonparticipant  is found  to be breastfeeding  while  being  exposed  or having 
been exposed to study intervention (ie, environmental exposure). An example of 
environmental EDB is a female family member or healthcare provider who reports 
that she is breastfeeding after having been exposed to the study intervention by 
ingestion.  
The investigator must report EDB to Pfizer Safety within 24 hours of the investigator’s 
awareness, irrespective of whether an SAE has occurred. The information must be reported 
using  the CT SAE  Report  Form.  When  EDB  occurs  in the setting  of environmental  exposure, 
the exposure information does not pertain to the participant enrolled in the study , so the  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 58  
 information  is not recorded  on a CRF.  However,  a copy  of the completed  CT SAE  Report 
Form is maintained in the investigator site file.  
An EDB report is not created when a Pfizer drug specifically approved for use in 
breastfeeding women (eg, vitamins) is administered in accordance with authorized use. 
However,  if the infant  experiences  an SAE  associated  with such a drug,  the SAE  is reported 
together with the EDB.  
8.4.5.3.  Occupational Exposure  
The investigator  must  report  any instance  of occupational  exposure  to Pfizer  Safety  within  24 
hours of the investigator’s awareness using the CT SAE Report Form regardless of whether 
there is an associated SAE. Since the information about the occupational exposure does not 
pertain to a participant enrolled in the study, the information is not recorded on a CRF; 
however, a copy of the completed CT SAE Report Form must be maintained in the 
investigator site file.  
8.4.6.  Cardiovascular  and Death  Events  
Not applicable.  
8.4.7.  Disease  -Related  Events  and/or  Disease  -Related  Outcomes  Not Qualifying  as AEs 
or SAEs  
Not applicable.  
8.4.8.  Adverse  Events  of Special  Interest  
Not applicable.  
8.4.8.1.  Lack  of Efficacy  
This section is not applicable because efficacy  is not expected in the study  population.  
8.4.9.  Medical  Device  Deficiencies  
Not applicable.  
8.4.10.  Medication  Errors  
Medication errors may result from the administration or consumption of the study 
intervention  by the wrong  participant,  or at the wrong  time,  or at the wrong  dosage  strength.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 59  
 Medication  errors  are recorded  and reported  as follows:  
 
Recorded on the 
Medication  Error  Page 
of the CRF  Recorded on the 
Adverse  Event  Page 
of the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within  24 Hours  of 
Awareness  
All (regardless  of whether 
associated with an AE)  Any AE or SAE  associated 
with the medication error  Only  if associated  with an 
SAE 
 
Medication  errors  include:  
• Medication  errors  involving  participant  exposure  to the study  intervention;  
• Potential  medication  errors  or uses outside  of what  is foreseen  in the protocol  that do 
or do not involve the study participant.  
Such  medication  errors  occurring  to a study  participant  are to be captured  on the medication 
error page of the CRF, which is a specific version of the AE page.  
Whether or not the medication error is accompanied by an AE, as determined by the 
investigator,  the medication  error  is recorded  on the medication  error  page  of the CRF  and, if 
applicable,  any associated  AE(s),  serious  and nonserious,  are recorded  on the AE page  of the 
CRF.  
In the event of a medication dosing error, the sponsor should be notified  within 24 hours.  
Medication  errors  should  be reported  to Pfizer  Safety  within  24 hours  on a CT SAE  Report 
Form only when associated with an SAE.  
8.5. Pharmacokinetics  
Blood samples of approximately 3 mL, to provide approximately 1 mL of plasma, will be 
collected  for measurement  of plasma  concentrations  of PF-07081532  as specified  in the SoA. 
Instructions for the collection and handling of biological samples will be provided in the 
laboratory manual or by the sponsor. The actual date and time (24 -hour clock time) of each 
sample will be recorded.  
The actual  times  may change,  but the number  of samples  will remain  the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  
Samples will be used to evaluate the PK of PF -07081532. Each plasma sample will be 
divided into 2 aliquots (1 each for primary  and backup). Samples collected for analyses of 
PF-07081532  plasma  concentration  may also be used to evaluate  safety  or efficacy  aspects 
related to concerns arising during or after the study, for metabolite identification and/or  
evaluation  of the bioanalytical  method,  or for other  internal  CCI purposes.  
PF-07081532  
Protocol C399 1041 
 Final Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linica l Phannacology Pro tocol Templa te (01 April  2022) 
Page  60  
 
Genetic analyses  will not be perfo1med on these plasma samples. 
Samples co llected fo r measurement of plasma concentrations of PF-07081532 will be 
analyzed using a validated analytica l method in compliance  with applicable SOPs. Potential 
metabolites  may be analyzed wit h either validated or explorato 1y methods. 
The PK samples must be processed and  shipped  as indicated in the instructions provided to 
the investigato r site to maintain sample integrity. Any deviatio ns from the PK sample 
handling proced ure (eg, sample collectio n and process ing steps,  interim storage or shipping 
conditions), including any actio ns taken, must be documented and reported to the sponsor. 
On a case -by-case basis, the sponsor may make a dete nnination as to w hether sample 
integrity has been compromised. 
Any changes in the timin g or addition of time points for any planned study assess ments must 
be documented and approved by  the releva nt study team  member and t hen archived in the 
sponsor and site study files, but will not constitute a protoco l amendment. The IRB/EC will 
be infonned of any safety issues that require alteratio n of the safety monitoring scheme or 
amendme nt of the ICD . 
8.6. Genetic s 
8.6.1.  Specified  Genetic s 
Specified  genetic analyses are not evaluated in this study. 
 
 
 
8.7. Biomarker s 
Biomarkers  are not evaluated  in this study. 
 
I   
I  

PF-07081532  
Protocol C399 1041 
 Final Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linica l Phannacology Pro tocol Templa te (01 April  2022) 
Page  61  
 
 
 
 
 
8.8. Immuno genicity Assess ments 
Immu nogenicity assessments are not includ ed in this study. 
8.9. Health Economics 
Health economics/medical resource utilization and health economics param eters a re not 
evaluated in this study. 
9. STATISTICAL  CONSIDERATIO NS 
Detailed methodology fo r summai y and statistical analyses of the data collected in this study 
is outlin ed here and furth er detailed in the SA P, which will be maintained by the sponsor. 
The SAP may modify what is outlined in the protocol where approp riate; howeve r, any major 
modifications of the primai y endpoint definitions or their analyses will also be reflected in a 
protoco l amendment. 
9.1. Statistical  Hypothesis 
No fonnal statistical hypothesis testing will be perfonned in this study. 
9.2. Analysis Sets 
For pmposes of analysis, the following analysis sets are defined: 
 
Particip ant Analysis 
Set Description  
Enrolled "Enrolled" means a paiticipant's, or their legally authorized 
representative's, agreement to pait icipate in a clinical study 
following completion of the info1med co nsent process and 
assignment to st udy intervention. A paiticipant will be 
considered enrolled if the info1med consent is not withdrawn 
prior to paiticipating in an y study activity after screening. 
Potential paiticipants w ho ai·e sc reened fo r the pmpose of 
dete1mining eligibility for the study, but do not paiticipate in 
the study, are not co nsidered enrolled, unless o the1wise 
specified by the protoco l. 

PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 62  
  
Participant  Analysis 
Set Description  
Safety  analysis  set All participants randomly assigned to study intervention and 
who take at least 1 dose of study  intervention.  Participants  will 
be analyzed according to the product they actually received.  
PK concentration  set All participants  who take at least 1 dose of study  intervention 
and in whom at least 1 concentration value is reported.  
PK parameter  set All participants  who take at least 1 dose of study  intervention 
and in whom at least 1 of the PK parameters of primary 
interest are reported.  
9.3. Statistical Analyses  
The SAP will be developed and finalized before any analyses are performed and will 
describe  the analyses  and procedures  for accounting  for missing,  unused,  and spurious  data. 
This section is a summary of the planned statistical analyses of the primary and secondary 
endpoints.  
9.3.1.  Pharmacokinetic  Analyses  
9.3.1.1.  Derivation  of Pharmacokinetic  Parameters  
Plasma PK parameters of PF -07081532 will be derived (as data permits) from the 
concentration -time data using  standard  noncompartmental  methods  as outlined  in Table  4. 
Actual  PK sampling  times  will be used in the derivation  of PK parameters.  In the case that 
actual PK sampling times are not available, nominal PK sampling time will be used in the 
derivation of PK parameters.  
 
Table 4. Plasma  PK Parameters  for PF-07081532  
 
Parameter  Definition  Method  of Determination  
AUC last Area under the plasma 
concentration -time profile from 
time zero to the time of the last 
quantifiable  concentration  (Clast). Linear/Log  trapezoidal  method.  
AUC infa Area under the plasma 
concentration -time profile from 
time zero extrapolated  to infinite 
time.  AUC last + (Clast*/k el), where  Clast* is 
the predicted plasma concentration 
at the last quantifiable time point 
estimated from the log -linear 
regression analysis.  
Cmax Maximum  plasma  concentration.  Observed  directly  from  data. 
Tmax Time  for Cmax. Observed  directly  from  data as time 
of first occurrence.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 63  
  
Table 4. Plasma  PK Parameters  for PF-07081532  
 
Parameter  Definition  Method  of Determination  
t½a Terminal  half-life. Log e(2)/k el, where  kel is the terminal 
phase rate constant calculated by a 
linear regression of the log -linear 
concentration -time curve. Only 
those  data points  judged  to describe 
the terminal log -linear decline will 
be used in the regression.  
CL/Fa Apparent  oral clearance.  Dose/AUC inf. 
Vz/F Apparent  volume  of distribution.  Dose/  (AUC inf • kel). 
a. as data permit  
 
9.3.1.2.  Statistical  Methods  for PK Data  
Natural log e transformed AUC inf of PF -07081532 administered without cyclosporine or 
coadministered  with cyclosporine  will be analyzed  using  a mixed  effect  model  with treatment 
as a fixed effect and participant as a random effect. Estimates of the adjusted mean 
differences (Test/Reference) and corresponding 90% CIs will be obtained from the models.  
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference)  and 90% CIs for 
the ratios. The test treatment will be ‘PF -07081532 40 mg singe dose and cyclosporine’ 
(Period 2), which will be reported separately in comparison to the reference treatment of  
‘PF-07081532  40 mg singe  dose without cyclosporine’  (Period  1). 
Natural log e transformed AUC inf of PF -07081532 administered without itraconazole or 
coadministered  with itraconazole  will be analyzed  using  a mixed  effect  model  with treatment 
as a fixed effect and participant as a random effect. Estimates of the adjusted mean 
differences (Test/Reference) and corresponding 90% CIs will be obtained from the models. 
The adjusted mean differences and 90% CIs for the differences will be exponentiated to 
provide  estimates  of the ratio of adjusted  geometric  means  (Test/Reference)  and 90% CIs for 
the ratios. The test treatment will be ‘PF -07081532 40 mg singe dose and itraconazole’ 
(Period 3), which will be reported separately in comparison to the reference treatment of  
‘PF-07081532  40 mg singe  dose without  itraconazole’  (Period  1). 
PK parameters, including plasma AUC inf, AUC last, Cmax, Tmax, and CL/F, V z/F, t ½, as data 
permit,  of PF-07081532  will be summarized  descriptively  by treatment.  For AUC inf, a listing 
of the individual participant ratios (Test/Reference) will be provided. Box and whisker plots 
for AUC inf will be plotted by treatment.  
The plasma concentrations of PF -07081532 will be listed and descriptively summarized by 
nominal  PK sampling  time and treatment. Individual  participant,  as well as mean  and median 
profiles, of the plasma concentration -time data will be plotted by treatment using actual (for 
individual) and nominal (for mean and median) times, respectively. Mean and median 
profiles will be presented on both linear and semi -log scales.  
PF-07081532  
Protocol C3991041  
PFIZER  CONFIDENTIAL  
CT02 -GSOP Clinical Phannacology Pro tocol Templa te (01 April  2022) 
Page  64  
 
 Final  Protocol 31 January  2023   
 
Additio nal specificatio ns regard ing the tables, listings, and figures will be outlined in the 
SAP.  
9.3.2.  Safety Analyses 
All safety  analyses will be perfo1med on the safety  popu lation. 
AEs, ECGs , BP, pulse rate, body  weight , and safety laborato1y data  will be rev iewed and 
summa rized on an ongo ing basis  dming the study to  evaluate the  safety  of paiiicipa nts. Body 
weight will be summ arized descr iptively by pe riod. Any clinical laborato 1y, ECG,  BP, and 
pulse rate ab nonnalities of potential cl inical co ncern will be described. Safety  data will be 
prese nted in tabulai·and/o r graphical fo1mat  and smnmai· ized desc riptively,  where 
appropriate.  
Med ical histo1y and phys ical exaininatio n and neurological  examination infonnatio n, as 
applicable , collected d uring the course  of the study, will be considered source data and will 
not be required to be  repo1ied,  unless othe1wise noted. However , any untowai·d findings 
identified on phys ical and/or neurological  exam inations conducted d uring the active 
collect ion period wi ll be captured as AEs , if those findings meet t he defin ition of an AE. 
Data  collected  at screening that ai·e used for inclusion/excl usion criteria, such as laborato1y 
data, ECGs, and vital signs, will be considered source data, an d will not be required to be 
repo1ied, unless othe1wise  noted.  Demographic  data collected  at scree ning will be repo1ied. 
9.3.2.1.  Electrocardiogram  Anal yses 
Changes  from  baseline for the ECG  pai·amete rs HR, QTcF, PR interval, and QRS complex 
will be summa rized by  period a nd time. The freque ncy of unco ITected QT  values above 
500 ms wi ll be tab ulated.  
The number (%) of pa1iicipants with maximum postdose  QTcF values  and maximum 
increases from  baseli ne in t he following catego ries wi ll be tab ulated by  period: 
 
Safety QTcF  Assess ment  
 
Degree of Prolonga tion Mild  (ms) Moderate (ms) Seve re (ms) 
Absolute  value  >450-480 >480-500 >500 
Increase  from  baseline   30-60 >60 
Baseline  will be pre-dose on Day I. 
 
9.3.2.2.  Mental  Health 
Assessme nt of mental health as dete1mined by C-SSRS and  PHQ-9. Detai ls will be prov ided 
in the SAP.  
 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 65  
 9.4. Interim  Analyses  
No interim analysis will be conducted for this study. As this is an open -label study, the 
sponsor  may conduct  unblinded  reviews  of the data during  the course  of the study  for the 
purpose of safety and PK assessments.  
9.5. Sample Size Determination  
Approximately  16 participants  will be enrolled  in the study  such that approximately 
12 evaluable participants complete the study.  
A sample  size of 12 participants  will provide  adequate  precision  to estimate  the relative 
bioavailability of PF -07081532. The following table presents the width of 90% CI for 
different estimated effects, with 80% coverage probability.  
 
Parameter  Estimated Effect 
(100*Test/Reference)  90%  CI CI Width  
AUC inf 85% 66.46%  108.71%  42.25%  
90% 70.37%  115.11%  44.74%  
95% 74.28%  121.50%  47.22%  
100%  78.19%  127.90%  49.71%  
105%  82.10%  134.29%  52.20%  
110%  86.01%  140.69%  54.68%  
115%  89.92%  147.08%  57.17%  
These  estimates  are based  on the assumption  that within -participant  standard  deviation  is 
0.291  for lnAUC inf as obtained  from  study  C3991001.  
Participants  who withdraw  from  the study  or discontinue  treatment,  or whose  PK samples  are 
considered to be non -evaluable with respect to the primary PK objective may be replaced at 
the discretion of the investigator upon consultation with the sponsor. For participants who 
remain in the study, the SAP will address PK data associated with episodes of vomiting 
following administration of study intervention and/or missed doses for any of the study 
interventions.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 66  
 10. SUPPORTING  DOCUMENTATION  AND  OPERATIONAL  CONSIDERATIONS  
10.1. Appendix  1: Regulatory, Ethical,  and Study Oversight Considerations  
10.1.1.  Regulatory  and Ethical  Considerations  
This study  will be conducted in accordance with the protocol and with the following:  
• Consensus  ethical  principles  derived  from  international  guidelines,  including  the 
Declaration of Helsinki and CIOMS International Ethical Guidelines;  
• Applicable  ICH GCP  guidelines;  
• Applicable  laws and regulations,  including  applicable  privacy  laws.  
The protocol,  protocol  amendments,  ICD,  SRSD(s),  and other  relevant documents  
(eg, advertisements)  must  be reviewed  and approved  by the sponsor,  submitted  to an IRB/EC 
by the investigator, and reviewed and approved by the IRB/EC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes  made  to the study  design,  except  for changes  necessary  to eliminate  an immediate 
hazard to study participants.  
Protocols and any substantial amendments to the protocol will require health authority 
approval  prior  to initiation  except  for changes  necessary  to eliminate  an immediate  hazard  to 
study participants.  
The investigator  will be responsible  for the following:  
• Providing  written  summaries  of the status  of the study  to the IRB/EC  annually  or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC;  
• Notifying  the IRB/EC  of SAEs  or other  significant  safety  findings  as required  by 
IRB/EC procedures;  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements  of 21 CFR,  ICH GCP guidelines,  the IRB/EC,  European  regulation 
536/2014  for clinical  studies,  European  Medical  Device  Regulation  2017/745  for 
clinical device research, and all other applicable local regulations.  
10.1.1.1.  Reporting  of Safety  Issues  and Serious  Breaches  of the Protocol  or ICH  GCP  
In the event  of any prohibition  or restriction  imposed  (ie, clinical  hold)  by an applicable 
regulatory authority in any area of the world, or if the investigator is aware of any new 
information that might influence the evaluation of the benefits and risks of the study 
intervention, Pfizer should be informed immediately.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 67  
 In addition, the investigator will inform Pfizer immediately of any urgent safety measures 
taken  by the investigator  to protect  the study  participants  against  any immediate  hazard,  and 
of any serious breaches of this protocol or of the ICH GCP guidelines that the investigator 
becomes aware of.  
10.1.2.  Informed  Consent  Process  
The investigator or the investigator’srepresentative will explain the nature of the study, 
including the risks and benefits, to the participant and answer all questions regarding the 
study.  The participant  should  be given  sufficient  time and opportunity  to ask questions  and to 
decide whether or not to participate in the trial.  
Participants must be informed that their participation is voluntary. Participants will be 
required  to sign a statement  of informed  consent  that meets  the requirements  of 21 CFR  50, 
local regulations, ICH guidelines, privacy and data protection requirements, where 
applicable, and the IRB/EC or study center.  
The investigator must ensure that each participant is fully informed about the nature and 
objectives  of the study,  the sharing  of data related  to the study,  and possible  risks  associated 
with participation, including the risks associated with the processing of the participant’s 
personal data.  
The participant  must  be informed  that their personal  study -related  data will be used by the 
sponsor  in accordance  with local  data protection  law. The level  of disclosure  must  also be 
explained to the participant.  
The participant  must  be informed  that theirmedical  records  may be examined  by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by 
appropriate IRB/EC members, and by inspectors from regulatory authorities.  
The investigator further must ensure that each study participant is fully informed about 
theirright  to access  and correct  theirpersonal  data and to withdraw  consent  for the processing 
of theirpersonal data.  
The medical record must include a statement that written informed consent was obtained 
before  the participant  was enrolled  in the study  and the date on which  the written  consent  was 
obtained. The authorized person obtaining the informed consent must also sign the ICD.  
Participants  must  be reconsented  to the most  current  version  of the IRB/EC -approved ICD(s) 
during their participation in the study as required per local regulations.  
A copy of the ICD(s) must be provided to the participant. 
Participants  who are rescreened  are required  to sign a new ICD.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 68  
 10.1.3.  Data  Protection  
All parties  will comply  with all applicable  laws,  including  laws regarding  the implementation 
of organizational and technical measures to ensure protection of participant data.  
Participants’  personal  data will be stored  at the study  site in encrypted  electronic  and/or  paper 
form and will be password protected or secured in a locked room to ensure that only 
authorized study staff have access. The study site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster. In the event of a potential personal data breach, the study site  will be responsible for 
determining whether a personal data breach has in fact occurred and, if so, providing breach 
notifications as required by law.  
To protect the rights and freedoms of participants with regard to the processing of personal 
data, participants will be assigned a single, participant -specific numerical code. Any 
participant  records  or data sets that are transferred  to the sponsor  will contain  the numerical 
code; participant names  will not be transferred. All other identifiable data transferred to the 
sponsor will be identified by this single, participant -specific code. The study site will 
maintain a confidential list of participants who participated in the study, linking each 
participant’s numerical code to their actual identity and medical record ID. In case of data 
transfer,  the sponsor  will protect  the confidentiality  of participants’  personal  data consistent 
with the clinical study agreement and applicable privacy laws.  
Information  technology  systems  used to collect,  process,  and store  study -related  data are 
secured by technical and organizational security measures designed to protect such data 
against accidental or unlawful loss, alteration, or unauthorized disclosure or access.  
The sponsor  maintains  standard  operating  procedures  on how to respond  in the event  of 
unauthorized access, use, or disclosure of sponsor information or systems.  
10.1.4.  Committees  Structure  
10.1.4.1.  Data  Monitoring  Committee  
This study  will not use an E -DMC.  
10.1.5.  Dissemination of Clinical Study Data  
Pfizer fulfills its commitment to publicly disclose clinical study results through posting the 
results of studies on www.clinicaltrials .gov (ClinicalTrials.gov), the EudraCT/CTIS, and/or 
www.pfizer .com,  and other  public  registries  and websites  in accordance  with applicable  local 
laws/regulations. In addition, Pfizer reports study  results outside of the requirements of local 
laws/regulations pursuant to its SOPs.  
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and 
complete  manner  and are reported  regardless  of the outcome  of the study  or the country  in 
which the study was conducted.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 69  
 www.clinicaltrials .gov 
Pfizer  posts  clinical  trial results  on www.clinicaltrials .gov for Pfizer -sponsored  interventional 
studies (conducted in patients) that evaluate the safety and/or efficacy of a product,  
regardless of the geographical location in which the study is conducted. These results are 
submitted for posting in accordance with the format and timelines set forth by US law.  
EudraCT/CTIS  
Pfizer  posts  clinical  trial results  on EudraCT/CTIS  for Pfizer -sponsored  interventional  studies 
in accordance with the format and timelines set forth by EU requirements.  
www.pfizer .com  
Pfizer  posts  CSR  synopses  and plain -language  study  results  summaries  on www.pfizer .com  
for Pfizer -sponsored interventional studies at the same time the  corresponding study  results 
are posted to www.clinicaltrials .gov.  CSR synopses will have personally identifiable 
information anonymized.  
Documents  within  marketing  applications  
Pfizer  complies  with applicable  local  laws/regulations  to publish  clinical  documents  included 
in marketing applications. Clinical documents include summary documents and CSRs 
including the protocol and protocol amendments, sample CRFs, and SAPs. Clinical 
documents will have personally identifiable information anonymized.  
Data  sharing  
Pfizer provides researchers secure access to participant -level data or full CSRs for the 
purposes  of “bona -fide scientific  research”  that contributes  to the scientific  understanding  of 
the disease, target, or compound class. Pfizer will make data from these trials available  
24 months  after study  completion.  Participant -level  data will be anonymized  in accordance 
with applicable privacy laws and regulations. CSRs will have personally identifiable 
information anonymized.  
Data  requests  are considered  from  qualified  researchers  with the appropriate  competencies  to 
perform the proposed analyses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercial/competitive or legal purposes.  
10.1.6.  Data Quality Assurance  
All participant  data relating  to the study  will be recorded  on printed  or electronic  CRF  unless 
transmitted  to the sponsor  or designee  electronically  (eg, laboratory  data).  The investigator  is 
responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 70  
 Guidance  on completion  of CRFs  will be provided  in the CRF  Completion  Requirements 
document.  
The investigator  must  ensure  that the CRFs  are securely  stored  at the study  site in encrypted 
electronic and/or paper form and are password -protected or secured in a locked room to 
prevent access by unauthorized third parties.  
QTLs  are predefined  parameters  that are monitored  during  the study.  Important  deviations 
from the QTLs and any remedial actions taken will be summarized in the CSR.  
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory agency inspections and provide direct access to source data documents. This 
verification  may also occur  after study  completion.  It is important  that the investigator(s)  and 
their relevant personnel are available during the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.  
Monitoring details describing strategy, including definition of study -critical data items and 
processes (eg, risk -based initiatives in operations and quality, such as risk management and 
mitigation strategies and analytical risk -based monitoring), methods, responsibilities, and 
requirements, including handling of noncompliance issues and monitoring techniques 
(central,  virtual,  or on-site monitoring),  are provided  in the data management  plan and IQMP 
maintained and utilized by the sponsor or designee.  
The sponsor  or designee  is responsible  for the data management  of this study,  including 
quality checking of the data.  
Records and documents, including signed ICDs, pertaining to the conduct of this study must 
be retained by the investigator for 15 years after study  completion unless local regulations or 
institutional policies require a longer retention period. No records may be destroyed during 
the retention period without the written approval of the sponsor. No records may be 
transferred to another location or party without written notification to the sponsor. The 
investigator  must  ensure  that the records  continue  to be stored  securely  for as long as they are 
maintained.  
When  participant  data are to be deleted,  the investigator  will ensure  that all copies  of such 
data are promptly and irrevocably deleted from all systems.  
The investigator(s) will notify the sponsor or its agents immediately of any regulatory 
inspection notification in relation to the study. Furthermore, the investigator will cooperate 
with the sponsor  or its agents  to prepare  the investigator  site for the inspection  and will allow 
the sponsor or its agent, whenever feasible, to be present during the inspection. The 
investigator site and investigator will promptly resolve any discrepancies that are identified 
between the study data and the participant’s medical records. The investigator will promptly 
provide copies of the inspection findings to the sponsor or its agent. Before response 
submission to the regulatory authorities, the investigator will provide the sponsor or its 
agents with an opportunity to review and comment on responses to any such findings.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 71  
 10.1.7.  Source  Documents  
Source  documents  provide  evidence  for the existence  of the participant  and substantiate  the 
integrity of the data collected. Source documents are filed at the investigator site.  
Data reported on the CRF or entered in the eCRF that are from source documents must be 
consistent with the source documents or the discrepancies must be explained. The 
investigator  may need  to request  previous  medical  records  or transfer  records,  depending  on 
the study. Also, current medical records must be available.  
In this study, the CRF will serve as the source document. A document must be available at 
the investigative  site that identifies  those  data that will be recorded  on the CRF  and for which 
the CRF will be the source document.  
Definition of what constitutes source data and its origin can be found in the Source 
Document  Locator,  which  is maintained  by the sponsor  or sponsor’s  designee  (Pfizer  CRU).  
Description  of the use of the computerized  system  is documented  in the Data  Management 
Plan, which is maintained by the sponsor or sponsor’s designee (Pfizer CRU).  
The investigator  must  maintain  accurate  documentation  (source  data)  that supports  the 
information entered in the CRF.  
The sponsor  or designee  will perform  mornitoring  to confirm  that data entered  into the CRF 
by authorized site personnel are accurate, complete, and verifiable from source documents; 
that the safety and rights of participants are being protected; and that the study is being 
conducted in accordance with the currently approved protocol and any other study 
agreements, ICH GCP guidelines, and all applicable regulatory requirements.  
10.1.8.  Study and Site Start and Closure  
The study  start date is the date on which  the clinical  study  will be open  for recruitment  of 
participants.  
The first act of recruitment  is the date of the first participant’s  first visit and will be the study 
start date.  
The sponsor designee reserves the right to close the study  site or terminate the study  at any 
time for any reason at the sole discretion of the sponsor, including (but not limited to) 
regulatory authority decision, change in opinion of the IRB/EC, or change in benefit -risk 
assessment. Study sites will be closed upon study completion. A study site is considered 
closed  when  all required  documents  and study  supplies  have  been  collected  and a study -site 
closure visit has been performed.  
The investigator may initiate study -site closure at any time upon notification to the sponsor 
or designee  if requested  to do so by the responsible  IRB/EC  or if such termination  is required 
to protect the health of study participants.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 72  
 Reasons  for the early  closure  of a study  site by the sponsor  may include  but are not limited 
to: 
• Failure  of the investigator  to comply  with the protocol,  the requirements  of the 
IRB/EC or local health authorities, the sponsor’s procedures, or the ICH GCP 
guidelines;  
• Inadequate  recruitment of  participants by  the investigator;  
• Discontinuation of further study  intervention development.  
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators,  the ECs/IRBs,  the regulatory  authorities,  and any CRO(s)  used in the study  of 
the reason for termination or suspension, as specified by the applicable regulatory 
requirements. The investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
Study  termination  is also provided  for in the clinical  study  agreement.  If there  is any conflict 
between the contract and this protocol, the contract will control as to termination rights.  
10.1.9.  Publication  Policy  
For multicenter trials, the primary publication will be a joint publication developed by the 
investigator  and Pfizer  reporting  the primary  endpoint(s)  of the study  covering  all study  sites. 
The investigator agrees to refer to the primary publication in any subsequent publications.  
Pfizer will not provide any financial compensation for the investigator’s  participation in the 
preparation  of the primary  congress  abstract,  poster,  presentation,  or primary  manuscript  for 
the study.  
Investigators are free to publish individual center results that they deem to be clinically 
meaningful after publication of the overall results of the study or 12 months after primary 
completion  date or study  completion  at all sites,  whichever  occurs  first, subject  to the other 
requirements described in this section.  
The investigator will provide Pfizer an opportunity to review any proposed publication or  
any other type of disclosure of the study results (collectively, “publication”) before it is 
submitted or otherwise disclosed and will submit all publications to Pfizer 30 days before 
submission. If any patent action is required to protect intellectual property rights, the 
investigator agrees to delay the disclosure for a period not to exceed an additional 60 days 
upon  request  from  Pfizer.  This allows  Pfizer  to protect  proprietary  information  and to provide 
comments, and the investigator will, on request, remove any previously undisclosed 
confidential information before disclosure, except for any study -intervention or  
Pfizer -related information necessary for the appropriate scientific presentation or 
understanding of the study results. For joint publications, should there be disagreement 
regarding interpretation and/or presentation of specific analysis results, resolution of, and 
responsibility  for, such disagreements  will be the collective  responsibility  of all authors  of 
the publication.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 73  
 For all publications relating to the study, the investigator and Pfizer will comply with 
recognized ethical standards concerning publications and authorship, including those 
established by the International Committee of Medical Journal Editors. The investigator will 
disclose  any relationship  with Pfizer  and any relevant  potential  conflicts  of interest,  including 
any financial or personal relationship with Pfizer, in any publications. All authors will have 
access to the relevant statistical tables, figures, and reports (in their original format) required 
to develop the publication.  
10.1.10.  Sponsor’s  Medically  Qualified  Individual  
The contact  information  for the sponsor’s  MQI  for the study  is documented  in the study 
contact list located in the supporting study documentation/CTMS.  
To facilitate access to their investigator and the sponsor’s MQI for study -related medical 
questions  or problems  from  nonstudy  healthcare  professionals,  participants  are provided  with 
an ECC at the time of informed consent. The ECC contains, at a minimum, (a) protocol and 
study intervention identifiers, (b) participant’s study identification number, and (c) site 
emergency phone number active 24 hours/day, 7 days per week.  
The ECC is intended to augment, not replace, the established communication pathways 
between  the participant  and their investigator and site  staff,  and between  the investigator  and 
sponsor study team. The ECC is only  to be used by healthcare professionals not involved in 
the research  study,  as a means  of reaching  the investigator  or site staff related  to the care of a 
participant.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 74  
 10.2. Appendix  2: Clinical  Laboratory  Tests  
The following  safety  laboratory  tests will be performed  at times  defined  in the SoA section  of 
this protocol. Additional laboratory results may be reported on these samples as a result of  
the method of analysis or the type of analyzer used by the clinical laboratory, or as derived 
from calculated values. These additional tests would not require additional collection of 
blood.  Unscheduled  clinical  laboratory  measurements  may be obtained  at any time during  the 
study to assess any perceived safety issues.  
 
Table 5. Protocol -Required  Safety  Laboratory  Assessments  
 
Hematology  Chemistry  Urinalysis  Other  
Hemoglobin 
Hematocrit 
RBC count 
Platelet  count 
WBC count  
Total  neutrophils  (Abs) 
Eosinophils (Abs) 
Monocytes (Abs) 
Basophils (Abs) 
Lymphocytes (Abs)  Urea and creatinine 
Cystatin  C and eGFR 
Glucose (fasting) 
Calcium  
Sodium 
Potassium 
Chloride  
Total  CO 2 (bicarbonate) 
AST, ALT  
TBili  
Alkaline  phosphatase 
Uric acid  
Albumin 
Total  protein  Local  dipstick:  
pH 
Glucose  (qual) 
Protein (qual) 
Blood (qual) 
Ketones 
Nitrites  
Leukocyte  esterase  
Laboratory:  
Microscopy  and 
culturea • Urine  drug screeningb 
• Pregnancy  test (β-hCG)c 
• COVID -19 testing  
 
At Screening:  
• FSHd 
• HIV,  HbsAg,  HCVAb,  
HbcAb,  HCV  RNAe 
• HbA1C  
• TSH 
• Calcitonin  
• C-peptide  
• Amylase  and lipase  
 Required:  
For suspected  DILI: 
AST/ALT  
TBili,  direct  and indirect  bili 
Total bile acids, GGT  
Total  protein,  albumin 
CK 
PT, INR 
Acetaminophen/paracetamol 
or 
protein  adduct  levels  
Hepatitis  serology  (even  if 
screening negative)    
a. Only  if UTI is suspected  and urine  dipstick  is positive  for nitrites  or leukocyte  esterase  or both.  
b. The minimum  requirement  for drug screening  includes  cocaine,  THC,  opiates/opioids,  benzodiazepines, 
and amphetamines (others are site and study specific).  
c. Serum  or urine  β-hCG  for female  participants  of childbearing  potential.  
d. For confirmation  of postmenopausal  status  only.  
e. The test will be performed  if HCV  is positive.  
 
The investigator  must  review  the laboratory  report,  document  this review,  and record  any 
clinically relevant changes occurring during the study in the AE section of the CRF.  
PF-07081532  
Protocol C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linica l Phannacology Protocol Templa te (01 April  2022) 
Page  75  
 10.3. Appendix 3: Adverse Events: Definitions and  Procedure s for Recording , 
Evaluating, Follow -Up, and Reporting  
10.3.1.  Definition  of AE 
 
AE Definition  
•  An AE is any untoward medical occmTence  in a patient  or clinical study 
paiiic ipant, tempora lly assoc iated with the use of study interventio n, whether or not 
conside red related to the study interventi on. 
 
• Note: An AE can therefore be any unfavorable and  unintended  sign (inclu ding an 
abno1mal  laborato1y findin g), symptom, or disease (new or exacerbated) 
temp orally assoc iated with t he use of study inter vention.  
 
 
Events  Meeting  the AE Definition  
•  Any abno1mal  laborato 1y test results (hemat ology, clinical chemistiy, or urinalysis) 
or other safety assessments (eg, ECG, radiol ogical scans, vital sign measurement s), 
includin g those  that worsen from ba seline, cons idered clin ically significa nt in the 
medi cal and scientific judgment of the investigator. An y abnonnal laborato1 y test 
results that meet any of the conditio ns below mu st be recorded as an AE : 
 
• Is associated  with acco mpan ying symptoms; 
 
• Requir es additio nal diagnost ic testing or medi caVs urgical intervention;  
 
•  Leads to a change in study dosing  (outside of any protocol-specified dose 
adjustinents) or discontinu ation from  the study, significant additional 
conc01nitant drn g ti·eatinent,  or other therap y. 
 
• Exace rbation of a chronic or inte1mittent preexi sting condition , includin g an 
increa se in either frequenc y and/or inten sity of the condition.  
• New conditio n detected  or diagnosed  after study intervention administl'ation, even 
though it may have bee n present before the  staii of the study. 
 
• Signs, symptom s, or the clinical  sequelae  of a suspected drng-drng intera ction. 
 
•  Signs, symptom s, or the clinical sequelae  of a suspected overdose of either  study 
intervention or a concom itant medicati on. Overdose  per se will not be repo1ied as 
an AE or SAE unless it is an  intentio nal overdose taken with possible 
suicidaVself -haiming intent. Such overdoses should be repo1ied re gardless of 
sequelae.  
PF-07081532  
Protocol C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linica l Phannacology Protocol Templa te (01 April  2022) 
Page  76  
  
Events  Meeting  the AE Definition  
• Any clinically  significa nt abno1mal  laborato 1y findings  or other abno1mal  safety 
assessme nts that are associated wit h the underlying  disease , unless  judged by  the 
investigator to be more  severe t han expected for the paiiicipant's cond ition.  
 
• The disease /disorder being  studied  or expected  progression , signs,  or symptoms  of 
the disease /disorder being studied , unless more  severe than expected for the 
paiiic ipant 's cond ition.  
 
• Medical  or surgical  procedure (eg, endoscopy, appe ndectomy):  the cond ition t hat 
leads to the procedure is the AE. 
 
•  Situations  in which an untowai·d  medical  occmTe nce did not occur (socia l and/or 
convenience admiss ion to a hospital).  
 
•  Anticipated  day-to-day fluctuations  of preexisting  disease(s)  or conditio n(s) present 
or detected at t he staii of the study that do not worse n. 
10.3.2.  Definition  of an SAE  
 
An SAE  is defined as  any untoward medical occurrence  that,  at any dose,  meets  one 
or more of the criteria listed below:  
a. Results  in death  
b. Is life-threatening  
The te1m "life-threatening" in the definition  of "serious" refers  to an event in which the 
paiiic ipant was at risk of  death at the time of the event.  It does  not refer  to an event that 
hypothetica lly might have caused death if it were more severe. 
c.  Requires  inpatient  hospitalization  or prolongation  of existing  hospitalization  
In general , hospitalization  signifies that the participant has been admitted ( usually 
involving  at least  an overnigh t stay)  at the hospital or emergency wai·d for obse rvation 
and/or treatment that would not have been appropr iate in the physician 's office o r 
outpatie nt setting. Comp lications that occur during hospitalizat ion are AEs. If a 
complicat ion prolongs  hospitalization or fulfills  any other serious criteria, the eve nt is 
serious. Whe n in doubt  as to whether "hospitalizat ion" occmTed or was necessaiy , the 
AE should be considered ser ious. 
Hospitalization  for elective  treatment of a preexisting  cond ition t hat did not worse n 
from baseline is not conside red an AE. 
PF-07081532  
Protocol C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linica l Phannacology Protocol Templa te (01 April  2022) 
Page  77  
  
d. Results in persistent or signific ant disability/incapacity 
 
• The te1m  disability mea ns a substantial dismpti on of a person 's ability to conduct 
nonnal life fu nctions. 
 
•  This definition is not intended  to include  experiences of relatively minor medical 
significanc e, such as uncomplicat ed headache, nausea, vomit ing, diaiThea , 
influenza, and accide ntal trauma  (eg, sprained ank le), that may interfere  with or 
prevent e ve1yday life func tions but do not  constitute a substantia l dismption. 
e.  Is a congenital  anomal y/birth defect 
f. Is a suspected tran smission via a Pfizer produ ct of an infectious agent, pathogenic 
or non-pathogenic  
The event may be suspected  from clinical symptoms or laborat o1y findings indicat ing 
an infection in a pa1ticipant exposed to a Pfize r product. T he tenn s "suspected 
transmission" and "transmission" are c onsidered synonymous. These cases are 
considered unexpected and  handled as serious expedite d cas es by phaimac ovigilance 
personnel. Such cases ai·e also considered for repo1t ing as produ ct defects, if 
approp riate. 
g. Other  situations: 
 
• Medical  or scientific judgment should be exercised by the investigator in decid ing 
whether SAE rep o1ting is approp riate in other situations, such as significant  medical 
events that ma y jeopai·dize the paiti cipant or ma y require medical  or surgical 
intervention to prevent one of the other outcomes listed in the above definition. 
These events should usually be considered serious. 
• Example s of such events include  invasive or mali gnant cancers, intensive treatment 
in an  emer gency room  or at home for a llergic bro nchospasm, blood dyscrasias or 
convu lsions that do  not result in hospitalization, or developme nt of diug 
depende ncy or diu g abuse. 
10.3.3.  Recordin g/Reportin g and Follow -Up of AEs and/or SAEs  Durin g the Active 
Collection P eriod 
 
AE and SAE  Recordin g/Reporting  
The table below s ummariz es the requirement s for re cording AEs on the CRF and fo r 
repo1tin g SAE s on the CT SAE Rep o1t Fo1m to Pfizer  Safety  throughout the active 
collection period. These requ irements are delineated for  3 types of events: (1) SAEs; (2) 
nonserious AEs; and (3) exp osure to the study inter vention under study during pregna ncy 
or breastfeed ing, and occupational exposure. 
PF-07081532  
Protocol  C3991041  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 78   
 Final  Protocol  31 January  2023  
 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same  as the AE page  of the CRF.  When  the same  data are collected,  the forms  must  be 
completed in a consistent manner. AEs should be recorded using concise medical 
terminology and the same AE term should be used on both the CRF and the CT SAE 
Report Form for reporting of SAE information.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* EDP (with or without an associated AE or SAE): any pregnancy information is reported to 
Pfizer  Safety  using  the CT SAE  Report  Form  and EDP  Supplemental  Form;  if the EDP  is associated 
with an SAE, then the SAE is reported to Pfizer Safety using the CT SAE Report Form.  
** EDB  is reported  to Pfizer  Safety  using  the CT SAE  Report  Form, which  would  also include 
details of any SAE that might be associated with the EDB.  
*** Environmental  or occupational  exposure:  AEs or SAEs  associated  with 
occupational exposure are reported to Pfizer Safety using the CT SAE Report Form.  
• When  an AE or SAE  occurs,  it is the responsibility  of the investigator  to review  all 
documentation (eg, hospital progress notes, laboratory reports, and diagnostic 
reports) related to the event.  
• The investigator  will then record  all relevant  AE or SAE  information  in the CRF.  
• It is not acceptable  for the investigator  to send photocopies  of the participant’s 
medical records to Pfizer Safety in lieu of completion of the CT SAE Report 
Form/AE or SAE CRF page.  Safety Event  Recorded  on the CRF  Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within  24 Hours  of 
Awareness  
SAE All All 
Nonserious  AE All None  
Exposure to the study 
intervention  under  study 
during pregnancy or 
breastfeeding  All AEs/SAEs  associated 
with EDP or EDB  
 
Note: Instances of EDP or 
EDB  not associated  with an 
AE or SAE  are not captured 
in the CRF  All instances  of EDP  are 
reported  (whether  or not 
there is an associated 
SAE)*  
All instances  of EDB  are 
reported (whether or not 
there is an associated 
SAE)**  
Environmental or 
occupational  exposure  to 
the product under study 
to a nonparticipant (not 
involving EDP or EDB)  None.  Exposure  to a study 
non-participant is not 
collected on the CRF  The exposure  (whether  or 
not there is an associated 
AE or SAE) must be 
reported***  
 
PF-07081532  
Protocol C399 1041 
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linical Phannacology Pro tocol Templa te (01 April  2022) 
Page  79  
  
• There may  be instances w hen copies  of medical reco rds for certain cases a re 
requested by Pfizer Safety . In this  case, all participant ide ntifiers , with the 
except ion of the paiiicipant number , will be redacted  on the copies of the medical 
records before subm ission to Pfize r Safety . 
•  The investigator will attempt to establish a diagnosis  of the event based  on signs , 
symptoms , and/or other clinical info1mat ion. Wheneve r possible, the diagnos is (not 
the individual signs /symptoms) will be docume nted as t he AE  or SAE . 
Assessment of Inten sity 
The investigator  will make  an assessment  of intensity for each AE and SAE  repo1ied 
during the study and assign it to 1 of t he following categor ies: 
 
• Mild:  A type of AE  that is us ually trans ient and may req uire only minimal 
treatme nt or therape utic interventio n. The event  does  not generally  interfere with 
usual AD L. 
• Moderate: A type  of AE that is usua lly alleviated wit h additio nal specific 
therapeutic  interve ntion. The event interfe res with usual ADL, causing discomfo 1i, 
but poses no significant o r pennanent risk of haim  to the research paiiicipant.  
•  Seve re: A type of AE  that intenupts usua l ADL , or significantly affects clinical 
status , or may req uire intensive therapeut ic interventio n. 
An event  is defined  as "serious" whe n it meets  at least  1 of the predefi ned outcomes  as 
descr ibed in t he definit ion of an SAE , NOT when it is rated as  severe . 
 
 
Assessment of Causality 
• The investigator  is obligated  to assess  the relations hip between  study  interventio n 
and each occmTe nce of  each AE  or SAE. The investigato r will use  clinical 
judgme nt to dete 1mine t he relations hip. 
• A "reasonable  possibi lity" of a relatio nship conveys t hat there are facts , evide nce, 
and/o r arguments to suggest  a causal  relatio nship, rather than a relatio nship cannot 
be rn led out.  
• Alternative causes , such as underly ing disease(s),  concoinita nt therapy,  and other 
risk facto rs, as well as the tempora l relations hip of the event  to study intervention 
adininistration , will be co nsidered and investigated . 
 
• The investigator  will also consult the IB and/o r prod uct info1matio n, for mai·keted 
products , in their assessme nt. 
PF-07081532  
Protocol C399 1041 
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linical Phannacology Pro tocol Templa te (01 April  2022) 
Page  80  
  
• For each AE or SAE , the investigato r !!!!!.U  document in the medical  notes  that they 
have reviewed  the AE or SAE  and have prov ided an assess ment of causality. 
 
• There may be situations in which an SAE h as occmTed an d the investigato r has 
minim al info1mation to include in the initial repo1i to the sponsor. Howeve r, it is 
very important that  the investigator alwa ys make an a ssessment of cau sality 
for every  event  before  the initial tran smission of the  SAE data to  the sponsor. 
• The investigator may change theirop inion of causality in light of follow-up 
info1mation and send an SAE follow-up repo1i with the updated  causality 
assess ment. 
• The causality assess ment is one of the criteria used when dete1minin g regulato1y 
repo1iing requirements. 
•  If the investigator does not know whether or not the study intervention caused the 
event, then the event will be handled as "related to study intervention" for repo1iing 
pmposes , as defined by the sponsor. In additio n, if the investigato r dete1min es that 
an SAE is associated with study proced ures, the investigato r mu st record this 
causal relationship in  the source documents and CRF, and repo1i such an 
assess ment in the dedicated  sectio n of the CT SAE R epo1i Fo1m and in acco rdance 
with the SAE reporting requirements.  
 
 
Follow -Up of AEs and SAE s 
•  The investigator is obligated to perfonn or aiTange for the conduct of supplemental 
measurements and/or evaluatio ns, as medica lly indicated or as requested by the 
sponsor, to elucidate the nature and/o r causality of the AE  or SAE as fully as 
possible. This may inclu de additio nal laborato 1y tests or investigations, 
histopathological exainin ations, or consultation with other healthcai·e provi ders. 
 
• If a paiiicipant dies d uring paiiicipatio n in the study or during a recogn ized 
follow-up pe riod, the investigato r will prov ide Pfizer Safety with a copy  of any 
postmo1iem fin dings, inclu ding histopathology. 
 
• New o r updated infonnatio n will be recorded in the originally submitted 
docume nts. 
• The investigator will subinit any updated SAE  data to the sponsor within 24 hours 
of receipt of the info1mation. 
PF-07081532  
Protocol C399 1041 
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linical Phannacology Pro tocol Templa te (01 April  2022) 
Page  81  
 10.3.4.  Reporting  of SAEs  
 
SAE  Reporting to  Pfizer  Safety  via an Electronic  DCT  
• The primaiy  mechanism for  reporting an SAE  to Pfizer  Safety  will be the 
electronic DCT. 
• If the  electronic system  is unavailable, then the site will use the paper  SAE  DCT 
(see next sectio n) to repo1t the event within 24 hours. 
 
• The site will enter the  SAE  data into the electron ic DCT  (eg, eSAE  or PSSA)  or 
paper f01m (as applicable) as soon  as the data become available. 
 
•  After  the study  is completed at  a given site, the electronic  DCT will be taken 
off-line to prevent the entiy  of new data  or changes to existing data.  
 
• If a site receives  a report of a new SAE  from  a study  paiticipant or receives updated 
data on a previously  repo1ted  SAE  after  the electi·on ic DCT  has been  taken off-line, 
then the site can repo1t this infonnation on a paper SAE f01m  (see next sect ion) or 
to Pfizer Safety by telephone.  
 
 
SAE  Reporting  to Pfizer Safety  via the CT SAE  Report  Form  
• Facsimile  transmission  of the CT SAE  Repo1t  Fo1m  is the prefeITed  method  to 
ti·ansmit this infonnation to Pfizer Safety.  
 
•  In circumsta nces when the facsimile is  not working , an alternative method  should 
be used , eg, secured (Transpo1t Layer Sec urity) or passwo rd-protected email.  If 
none of these methods can  be used,  notification by  telep hone is acceptable w ith a 
copy  of the CT SAE  Repo1t Fo1m  sent by ove rnigh t mail or co urier serv ice. 
•  Initial notificatio n via telephone does not  replace t he need fo r the investigator to 
complete  and sign the CT SAE  Repo1t  Fo1m pages  within the designated  repo1ting 
time frames.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 82  
 10.4. Appendix  4: Contraceptive  and Barrier  Guidance  
10.4.1.  Male  Participant  Reproductive  Inclusion  Criteria  
No contraception methods are required for male participants in this study, as the calculated 
safety  margin  is ≥100 -fold between  the estimated  maternal  exposure  due to seminal  transfer 
and the NOAEL  for serious  manifestations  of developmental  toxicity  in nonclinical  studies.  
10.4.2.  Female  Participant  Reproductive  Inclusion  Criteria  
The criteria below are part of Inclusion Criterion 1 (Age and Sex; Section 5.1 ) and specify 
the reproductive  requirements  for including  female  participants.  Refer  to Section  10.4.4  for a 
complete list of contraceptive methods permitted in the study.  
A female  participant  is eligible  to participate  if she is not pregnant  or breastfeeding  and at 
least 1 of the following conditions applies:  
• Is not a WOCBP  (see definition  in Section  10.4.3). 
OR 
• Is a WOCBP  and agrees  to use a highly  effective  contraceptive  method  (failure  rate of 
<1%  per year)  during  the intervention  period  and for at least 28 days after the last 
dose of study  intervention,  which  corresponds  to the time needed  to eliminate  any 
reproductive safety risk of the study intervention(s). If a highly effective,  
user-dependent  method  is chosen,  she agrees  to concurrently  use an effective  barrier 
method of contraception. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.  
The investigator  is responsible  for review  of medical  history,  menstrual  history,  and recent 
sexual activity to decrease the risk for inclusion of a woman with an early undetected 
pregnancy.  
10.4.3.  Woman  of Childbearing  Potential  
A woman  is considered  fertile  following  menarche  and until becoming  postmenopausal 
unless permanently sterile (see below).  
If fertility  is unclear  (eg, amenorrhea  in adolescents  or athletes)  and a menstrual  cycle  cannot 
be confirmed before the first dose of study intervention, additional evaluation should be 
considered.  
Women  in the following  categories  are not considered  WOCBP:  
1. Premenopausal  female  with 1 of the following:  
• Documented  hysterectomy;  
• Documented bilateral salpingectomy;  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 83  
 • Documented  bilateral  oophorectomy.  
For individuals with permanent infertility due to a medical cause other than the above 
(eg, mullerian  agenesis,  androgen  insensitivity),  investigator  discretion  should  be applied 
to determining study entry.  
Note:  Documentation  for any of the above  categories  can come  from  the site personnel’s 
review of the participant’s medical records, medical examination, or medical history 
interview.  The method  of documentation  should  be recorded  in the participant’s  medical 
record for the study.  
2. Postmenopausal  female.  
• A postmenopausal  state is defined  as no menses  for 12 months  without  an 
alternative medical cause. In addition:  
• A high FSH level in the postmenopausal range must be used to confirm a 
postmenopausal  state in women  under  60 years  old and not using  hormonal 
contraception or HRT.  
10.4.4.  Contraception  Methods  
Contraceptive  use by men or women  should  be consistent  with local  availability/regulations 
regarding the use of contraceptive methods for those participating in clinical trials.  
The following  contraceptive  methods  are appropriate  for this study: 
Highly Effective Methods  That Have Low User Dependency  
1. Implantable  progestogen  only hormone  contraception  associated  with inhibition  of 
ovulation.  
2. Intrauterine  device.  
3. Intrauterine  hormone  releasing  system.  
4. Bilateral  tubal  occlusion.  
5. Vasectomized  partner.  
• Vasectomized  partner  is a highly  effective  contraceptive  method  provided  that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highly effective method of contraception 
should be used. The spermatogenesis cycle is approximately 90 days.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 84  
 6. Sexual Abstinence  
• Sexual abstinence is considered a highly effective method only if defined as 
refraining  from  heterosexual  intercourse  during  the entire  period  of risk associated 
with the study intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual 
lifestyle of the participant.  
PF-07081532  
Protocol  C399 1041 
PFIZER  CONFIDENTIAL  
CT02-GSOP Clinical Phannacology Pro tocol Templa te (01 April  2022) 
Page  85  
 
 Final  Protocol 31 January  2023   
 
I 
I 
I 
I 
I   
I  
I  
I 
I 

PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 86  
 10.6. Appendix  6: Liver  Safety:  Suggested  Actions  and Follow -Up Assessments 
Potential Cases of Drug -Induced Liver Injury  
Humans exposed to a drug who show no sign of liver injury (as determined by  elevations in 
transaminases)  are termed  “tolerators,”  while  those  who show  transient  liver injury  but adapt 
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a 
more serious potential outcome. These participants fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury, commonly referred to as DILI. 
Participants who experience a transaminase elevation above 3 × ULN should be monitored 
more frequently to determine if they are “adaptors” or are “susceptible.”  
In the majority  of DILI  cases,  elevations  in AST  and/or  ALT  precede  T bili elevations 
(>2 × ULN) by several days or weeks. The increase in T bili typically occurs while 
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and T bili values will be  
elevated  within  the same  laboratory  sample).  In rare instances,  by the time T bili elevations 
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a 
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to T bili 
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law 
criteria) cases and should always be considered important medical events, even before all 
other possible causes of liver injury have been excluded.  
The threshold of laboratory abnormalities for a potential DILI case depends on the 
participant’s  individual  baseline  values  and underlying  conditions.  Participants  who present 
with the following laboratory abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:  
• Participants  with AST/ALT  and T bili baseline  values  within  the normal  range  who 
subsequently present with AST OR ALT values ≥3 × ULN AND a T bili value  
≥2 × ULN  with no evidence  of hemolysis  and an alkaline  phosphatase  value  
<2 × ULN  or not available.  
• For participants  with baseline  AST  OR ALT  OR T bili values  above  the ULN,  the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:  
• Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values  ≥2 times  the baseline  values  AND  ≥3 × ULN;  or ≥8 × ULN  (whichever  is 
smaller).  
• Preexisting  values  of T bili above  the normal  range:  T bili level  increased  from 
baseline value by an amount of  ≥1 × ULN or if the value reaches ≥3 × ULN 
(whichever is smaller).  
Rises in AST/ALT and T bili separated by more than a few weeks should be assessed 
individually  based  on clinical  judgment;  any case where  uncertainty  remains  as to whether  it 
represents a potential Hy’s law case should be reviewed with the sponsor.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 87  
 The participant should return to the investigator site and be evaluated as soon as possible, 
preferably  within  48 hours  from  awareness  of the abnormal  results.  This evaluation  should 
include laboratory tests, detailed history, and physical assessment.  
In addition to repeating measurements of AST and ALT and T bili for suspected Hy’s law 
cases, additional laboratory tests should include albumin, CK, direct and indirect bilirubin, 
GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should also be given 
to drawing a separate tube of clotted blood and an anticoagulated tube of blood for further 
testing, as needed, for further contemporaneous analyses at the time of the recognized initial 
abnormalities to determine etiology. A detailed history, including relevant information, such 
as review of ethanol, acetaminophen/paracetamol (either by itself or as a coformulated 
product in prescription or over -the-counter medications), recreational drug, or supplement 
(herbal)  use and consumption,  family  history,  sexual  history,  travel  history,  history  of contact 
with a jaundiced person, surgery, blood transfusion, history of liver or allergic disease, and 
potential occupational exposure to chemicals, should be collected. Further testing for acute 
hepatitis  A, B, C, D, and E infection,  liver imaging  (eg, biliary  tract),  and collection  of serum 
samples for acetaminophen/paracetamol drug and/or protein adduct levels may  be warranted.  
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/ALT and 
T bili elevation defined above should be considered potential DILI (Hy’s law) cases if no 
other  reason  for the LFT abnormalities  has yet  been  found.  Such  potential  DILI  (Hy’s  law) 
cases are to be reported as SAEs, irrespective of availability of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.  
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of 
reasonable  investigations  have  been  received  and have  excluded  an alternative  etiology.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 88  
 10.7. Appendix  7: Kidney  Safety:  Monitoring  Guidelines  
10.7.1.  Laboratory  Assessment  of Change  in Kidney  Function  and Detection  of Kidney 
Injury  
Standard kidney safety monitoring requires assessment of baseline and postbaseline serum 
creatinine (Scr measurement to estimate glomerular filtration rate [Scr -based eGFR] or 
creatinine clearance [eCrCl]). Baseline and postbaseline serum Scys makes it feasible to 
distinguish  AKI from  other  causes  of Scr increase.  If Scr increase  is confirmed  after baseline, 
then reflex measurement of Scys is indicated to estimate the combined Scr -Scys eGFR 
calculation (for adults only).  
Regardless of whether kidney function monitoring tests are required as a routine safety 
monitoring  procedure  in the study,  if the investigator  or sponsor  deems  it necessary  to further 
assess kidney safety and quantify kidney function, then these test results should be managed 
and followed per standard of care.  
10.7.2.  Age-Specific  Kidney  Function  Calculation  Recommendations  
10.7.2.1.  Adults  (18 Years  and Above) —2021  CKD -EPI Equations29 
 
2021  CKD - 
EPI 
Scr-Scys 
Combined  Scr 
 
(mg/dL)  Scys 
 
(mg/L)  Recommended  eGFR  Equation  
Female  if ≤ 0.7 if ≤ 0.8 eGFR  = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.323 × (0.9961)Age 
Female  if ≤ 0.7 if > 0.8 eGFR  = 130 × (Scr/0.7)-0.219 × (Scys/0.8)-0.778 × (0.9961)Age 
Female  if > 0.7 if ≤ 0.8 eGFR  = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age 
Female  if > 0.7 if > 0.8 eGFR  = 130 × (Scr/0.7)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age 
Male  if ≤ 0.9 if ≤ 0.8 eGFR  = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.323 × (0.9961)Age 
Male  if ≤ 0.9 if > 0.8 eGFR  = 135 × (Scr/0.9)-0.144 × (Scys/0.8)-0.778 × (0.9961)Age 
Male  if > 0.9 if ≤ 0.8 eGFR  = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.323 × (0.9961)Age 
Male  if > 0.9 if > 0.8 eGFR  = 135 × (Scr/0.9)-0.544 × (Scys/0.8)-0.778 × (0.9961)Age 
10.7.3.  Adverse  Event  Grading  for Kidney  Safety  Laboratory  Abnormalities  
AE grading  for decline  in kidney  function  (ie, eGFR  or eCrCl)  will be according  to KDIGO 
criteria.29 
PF-07081532  
Protoco l C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linical Phannacology Protocol Templa te (01 April  2022) 
Page  89  
 10.8. Appendix  8: ECG  Findings  of Potential  Clinical  Concern  
 
ECG  Findings  That  May  Qualify  as AEs 
1. Marked  sinus bradycardia  (rate  <40 bpm)  lasting  minutes.  
1. New  PR inter val prolongation  >280 ms. 
 
2. New  prolongatio n of QTcF  to >480 ms (absolute) or by60 ms from baseline.  
3. New -onset atrial  flutter or fibrillati on, with controlled  venti·icular response rate: ie, 
rate <120 bpm. 
4. New -onset type I second-degree (We nckebach) AV  block of >30 seconds' 
duration. 
5.  Frequen t PVCs, triplets, or sho1i inte1val s (<30 seconds) of co nsecutive venti·icular 
comple xes. 
ECG  Findings  That  May  Qualify  as SAEs  
6. QTcF  prolongation  >500 ms. 
7. New  ST-T changes sugge stive of myoca rdial ischemia. 
8. New -onset LBBB  (QRS  comple x>120 ms). 
9. New -onset right bundle  branch block (QRS complex>120 ms). 
 
10. Symptomatic bradycardia . 
11. Asysto le: 
 
• In awake, symptom -free paiiicipant s in sinus rhythm, wit h documen ted periods 
of asystole3.0seconds or any escape rate  <40 bpm, or with an escape  rhythm 
that is below  the AV node.  
 
• In awake,  symptom -free paiiicipant s with atrial  fibrillation  and bradycai ·dia 
with 1 or more pauses  of at least 5 seconds or longer.  
 
• Atrial  flutter or fibrillation , with rapid  venti·icular  respon se rate: rapid  = rate 
>120 bpm. 
12. Susta ined supraventriculai·tac hycai· dia (rate >120 bpm)  ("sustained "= short 
duration with relevant symptoms or lasting>1 minute) . 
13. Ventriculai·rhythms  >30 seconds' duration,  including  idioventi·icular  rhythm (HR 
<40 bpm) , accelerated  idioventriculai ·rhythm  (HR >40 bpm to <100 bpm), and 
PF-07081532  
Protoco l C3991041  
 Final  Protocol 31 January  2023   
PFIZER  CONFIDENTIAL  
CT02 -GSOP C linical Phannacology Protocol Templa te (01 April  2022) 
Page  90  
  
monomo1phic/polymorph ic ventricu lar tachycard ia (HR >100 bpm [such as 
torsades de po intes]). 
14. Type  II second-degree  (Mob itz II) AV block.  
15. Complete  (third-degree)  heait block. 
ECG Finding s That  Qualif y as SAE s 
16. Change in patte rn suggestive  of new myocai ·dial infai·ction. 
17. Susta ined ventriculai·tachyaiThythm ias (>30 seconds'  duration).  
18. Seco nd- or third-degree  AV block requiring pacemaker  placeme nt. 
19. Asysto lic pauses requiring  pacemaker  placement.  
20. Atrial flutter or fibrillation with rapid  ventriculai·respo nse requiring cardiovers ion. 
21. Ventriculai·fibrillation/flutter.  
22. At the discretion of the investigato r, any aiThythmia class ified as an adverse 
expenence. 
The enumerated list of major e vents of potential clinical  concem are recommended a s "alerts" or 
notifications from  the core ECG  laboratory  to the in vestigator and  Pfizer  study team , and not to be 
considered as all -inclu sive of what  to be repo1ted as AE s/SAE s. 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 91  
 10.9. Appendix  9: Abbreviations  
The following is a list of abbreviations that may  be used in the protocol.  
 
Abbreviation  Term  
Abs absolute  
ADL  activities of daily  living  
AE adverse  event  
AKI acute kidney  injury  
ALT  alanine aminotransferase  
AM before  noon  
AST aspartate aminotransferase  
AUC  area under  the concentration -time curve  
AUC inf area under  the plasma  concentration -time profile  from  time zero 
extrapolated to infinite time  
AUC tau area under  the plasma  concentration -time profile  over the dosing 
interval, tau  
AUC 24 area under  the plasma  concentration -time profile  from  time zero to 
time 24 hours  
AV atrioventricular  
AxMP  auxiliary  medicinal products  
-hCG beta human  chorionic  gonadotropin  
BMI body  mass  index  
BP blood  pressure  
bpm beats  per minute  
BUN  blood  urea nitrogen  
CFR Code of Federal Regulations  
CI confidence  interval  
CIOMS  Council  for International  Organizations  of Medical  Sciences  
CK creatine  kinase  
CKD -EPI Chronic Kidney  Disease Epidemiology  Collaboration  
CL clearance  
CL/F  apparent  oral clearance  
Clast predicted  plasma  concentration  at the last quantifiable  time point 
estimated from the log -linear regression analysis  
CLp plasma  clearance  
Cmax maximum  plasma  concentration  
CO 2 carbon  dioxide  (bicarbonate)  
COVID -19 coronavirus  disease  2019  
CRF case report  form 
CRO  contract research organization  
CRU  clinical  research  unit 
CSR Clinical Study  Report  
C-SSRS  Columbia Suicide Severity  Rating Scale  
CT clinical  trial 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 92  
  
Abbreviation  Term  
CTIS  Clinical  Trials  Information  System  
CTMS  Clinical Trial Management System  
CV coefficient  of variation  
CYP  cytochrome  P450  
DDI drug-drug interaction  
DILI  drug-induced  liver injury  
EC ethics  committee  
ECC  Emergency  Contact Card  
eCrCl  estimated  creatinine  clearance  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDB  exposure during breastfeeding  
E-DMC  External Data Monitoring Committee  
EDP exposure during pregnancy  
EE ethinyl  estradiol  
eGFR  estimated  glomerular  filtration  rate 
ET early  termination  
EU European  Union  
EudraCT  European  Clinical  Trials  Database  
EV extracellular  vesicles  
FSBG  fingerstick  blood  glucose  
FSH follicle -stimulating  hormone  
F/U follow -up 
GCP  Good  Clinical  Practice  
GGT  gamma -glutamyl  transferase  
GLP-1 glucagon -like peptide  1 
GLP-1R glucagon -like peptide  1 receptor  
HAE  hypoglycemic  adverse  event  
HbA1c  hemoglobin  A1c 
HBcAb  hepatitis  B core antibody  
HBsAg  hepatitis B surface antigen  
HCV  hepatitis C virus  
HCVAb  hepatitis C antibody  
HIV human  immunodeficiency  virus  
HR heart  rate 
HRT  hormone  replacement  therapy  
IB Investigator’s  Brochure  
ICD informed  consent  document  
ICH International  Council  for Harmonisation  of Technical  Requirements 
for Pharmaceuticals for Human Use  
ID identification  
IL Interleukin  
IMP investigational  medicinal  product  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 93  
  
Abbreviation  Term  
IND Investigational  New  Drug  
INR international  normalized  ratio 
IP investigational product  
IPAL  Investigational Product Accountability  Log 
IQMP  Integrated Quality  Management Plan 
IRB Institutional  Review  Board  
IV intravenous(ly)  
KDIGO  Kidney  Disease: Improving  Global  Outcomes  
kel first-order  elimination  rate constant  
LBBB  left bundle  branch  block  
LE levonorgestrel  
LFT liver function  test 
LLN  Lower  limit  of normal  
MD multiple dose 
MEN2  multiple  endocrine  neoplasia  syndrome  type 2 
MHP  mental  health  professional  
MQI  medically  qualified individual  
MTC  medullary  thyroid  carcinoma  
NA not applicable  
NOAEL  no observed  adverse  effect  level  
OATP  organic  anion  transporting  polypeptides  
PCR polymerase  chain  reaction  
PCRU  Pfizer Clinical Research Unit 
PE physical  examination  
pH potential  of hydrogen  
PHQ -9 Patient  Health  Questionnaire -9 
PI principal investigator  
PK pharmacokinetic(s)  
PR pulse  rate 
PT prothrombin time 
PVC  premature  ventricular  contraction/complex  
QD once  daily  
QTc corrected  QT 
QTcF  corrected QT (Fridericia method)  
qual qualitative  
QTL  quality  tolerance limits  
RA rheumatoid  arthritis  
RBC  red blood  cell 
SAE serious  adverse  event  
SAP Statistical  Analysis  Plan 
SARS -CoV-2 severe  acute  respiratory  syndrome  coronavirus  2 
Scr serum creatinine  
Scys serum  cystatin  C 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 94  
  
Abbreviation  Term  
SD single  dose;  standard  deviation  
SIB Suicidal  Ideation  and Behavior  
SoA schedule  of activities  
SOP standard operating procedure  
SRSD  single  reference  safety  document  
ST-T ST segment  to T wave  changes  on 12-lead ECG  
SSID  study -specific  subject  identification  number  
SUSAR  Suspected  Unexpected  Serious  Adverse  Reaction  
t1/2 terminal  elimination  half-life 
T2DM  type 2 diabetes  mellitus  
T4 thyroxine  
TBA  total bile acids  
TBili  total bilirubin  
TEAE  treatment  emergent  adverse  event  
THC  tetrahydrocannabinol  
Tmax time to Cmax 
TNF- tumor  necrosis  factor  alpha  
TSH thyroid  stimulating  hormone  
UA urine  analysis  
UGT  uridine  5'-diphospho  glucuronosyltransferase  
ULN  upper  limit  of normal  
US United  States  
USPI  United  States  Package  Insert  
UTI urinary  tract infection  
Vss volume of distribution at steady  state 
Vz/F  apparent volume of distribution  
WBC  white  blood  cell 
WOCBP  woman/women  of childbearing  potential  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 95  
 11. REFERENCES  
 
 
1 Orskov C, Holst JJ, Knuhtsen S, et al. Glucagon -like peptides GLP -1 and GLP -2, 
predicted  products  of the glucagon  gene,  are secreted  separately  from  pig small  intestine  but 
not pancreas. Endocrinology. 1986;119(4):1467 -75. 
2 Kreymann  B, Williams  G, Ghatei  MA, et al. Glucagon -like peptide -1 7-36: a 
physiological incretin in man. Lancet. 1987;2(8571):1300 -4. 
3 Nauck  MA, Niedereichholz  U, Ettler  R, et al. Glucagon -like peptide  1 inhibition  of 
gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 
1997;273(5):E981 -8. 
4 Flint  A, Raben  A, Astrup  A, et al. Glucagon -like peptide  1 promotes  satiety  and 
suppresses energy intake in humans. J Clin Invest. 1998;101(3):515 -20. 
5 IDF Diabetes  Atlas;  9th Edition.  Available  from:  IDF Diabetes  Atlas . Accessed  on 
05 Nov 2022.  
6 Menke  A, Casagrande  S, Geiss  L,et al. Prevalence  of and trends  in diabetes  among 
adults in the United States, 1988 -2012. JAMA. 2015;314(10):1021 -9. 
7 Stratton IM,  Adler  AI, Neil HA,  et al.  Association  of glycaemia  with macrovascular 
and microvascular  complications  of type 2 diabetes  (UKPDS  35): prospective  observational 
study. BMJ. 2000;321:405 -12. 
8 Guh DP, Zhang  W, Bansback  N, et al. The incidence  of co-morbidities  related  to 
obesity and overweight: a systematic review and meta -analysis. BMC Public Health. 
2009;9:88.  
9 Flegal KM, Kit BK, Orpana H, et al. Association of all -cause mortality with 
overweight  and obesity  using  standard  body  mass  index  categories:  a systematic  review  and 
meta analysis. JAMA. 2013;309(1):71 -82. 
10 The GBD  2015  Obesity  Collaborators.  Health  effects  of overweight  and obesity  in 
195 countries over 25 years. N Engl J Med. 2017;377(1):13 -27. 
11  Anderson  JW, Konz  EC, Frederich  RC, et al. Long -term weight -loss maintenance:  a 
meta -analysis of US studies. Am J Clin Nutr. 2001;74(5):579 -84. 
12 Drucker  DJ. The ascending  GLP -1 road from  clinical  safety  to reduction  of 
cardiovascular complications. Diabetes. 2018;67:1710 -9. 
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 96  
  
 
 
13 Sporanox®  (itraconazole)  Solution  USP.  United  States  Prescribing  Information, 
2003. Available at label (fda.gov). Accessed on 15 Jan 2022.  
14 Neoral®  Soft Gelatin  Capsules  (cyclosporine  capsules,  USP)  Modified.  Revised  Sept 
2009. Available at label (fda.gov). Accessed on 12 Dec 2022.  
15 Drug  Development  and Drug  Interactions  | Table  of Substrates,  Inhibitors  and 
Inducers | FDA  
16 Liu L, Bello A, Dresser MJ, et.al. Best Practices for the Use of Itraconazole as a 
Replacement  for Ketoconazole  in Drug –Drug  Interaction  Studies.  J Clin Pharmac.  2016, 
56(2) 143 –151. 
17 Backman  JT, Kivisto  KT, Olkkola  KT, Neuvonen  PJ. The area under  the plasma 
concentration -time curve for oral midazolam is 400 -fold larger during treatment with 
itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54(1):53 –58. 
18 Kivisto KT, Kantola T, Neuvonen PJ. Different effects of itraconazole on the 
pharmacokinetics  of fluvastatin  and lovastatin.  Br J Clin Pharmacol.  1998;46(1):49 –53. 
19 Jalava  KM, Olkkola  KT, Neuvonen  PJ. Itraconazole  greatly  increases  plasma 
concentrations and effects of felodipine. Clin Pharmacol Ther. 1997;61(4):410 –415 
20 Barone JA, Koh JG, Bierman RH, et al. Food interaction and steady state 
pharmacokinetics  of itraconazole  capsules  in healthy  male  volunteers.  Antimicrob  Agents 
Chemother. 1993;37(4):778 –784. 
21 Barone JA, Moskovitz BL, Guarnieri J, et al. Food interaction and steady -state 
pharmacokinetics  of itraconazole  oral solution  in healthy  volunteers.  Pharmacotherapy. 
1998;18(2):295 –301. 
22 J. Michael Davenport, Paul Covington, Laura Bonifacio, et al. Effect of Uptake 
Transporters  OAT3  and OATP1B1  and Efflux  Transporter  MRP2  on the Pharmacokinetics 
of Eluxadoline. The Journal of Clinical Pharmacology. 2015, 55(5) 534 –542. 
23 Sam Rebello,  Séverine  Compain,  Aimin  Feng,  et al. Effect  of Cyclosporine  on the 
Pharmacokinetics of Aliskiren in Healthy Subjects. Journal of Clinical Pharmacology. 
2011;51:1549 -1560.  
24 American  Diabetes  Association.  Standards  of medical  care in diabetes -2019.  Diabetes 
Care. 2019;42(Suppl 1): S1 -S193.  
PF-07081532  
Protocol  C3991041  
Final  Protocol  31 January  2023  
PFIZER  CONFIDENTIAL  
CT02 -GSOP  Clinical  Pharmacology  Protocol  Template  (01 April  2022) 
Page 97  
  
 
 
25  Posner K, Brown GK, Stanley  B, et al. The Columbia -Suicide  Severity  Rating  Scale: 
initial  validity  and internal  consistency  findings  from  three  multisite  studies  with adolescents 
and adults. Am J Psychiatry. 2011;168(12):1266 -77. 
26    C-SSRS -Full-Lifetime -Recent -1.doc (live.com).  
27    C-SSRS -Full-Since -Last-Contact -1.doc  (live.com).  
28 Kroenke  K, Spitzer  RL, Williams  JB. The PHQ -9: validity  of a brief  depression 
severity measure. J Gen Intern Med. 2001;16(9):606 -13. 
29 Inker  LA et al. KDIGO  2012  Clinical  Practice  Guideline  for the Evaluation  and 
Management of Chronic Kidney Disease. N Engl J Med. 2021;385:1737 -49. 